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ZUSAMMENFASSUNG 
 
Dendritische Zellen (dendritic cells, DCs) sind professionelle antigenpräsentierende 
Zellen des Immunsystems mit einer Schlüsselrolle bei der angeborenen und der 
adaptiven Immunität, da sie zur Auslösung T-zellspezifischer Immunantworten 
befähigt sind. Dabei ist das Migrationsvermögen von DCs entscheidend für ihre 
Immunfunktionen. 
Die Rezeptor-Tyrosinkinase Met ist ein Oberflächenrezeptor für den 
Hepatozytenwachstumsfaktor HGF (hepatocyte growth factor), auch bekannt als 
scatter factor (SF). Die ligandenabhängige Aktivierung des Met-Signalweges löst in 
verschiedenen zellulären Systemen mitogene, morphogene und motogene 
Aktivitäten aus, z. B. während der Embryonalentwicklung und bei der Wundheilung. 
Vorangegangene Arbeiten zeigten, dass DCs der Haut Met/SF-Rezeptor funktionell 
exprimieren. In der hier vorliegenden Arbeit wurde unter Verwendung eines 
konditionellen Met knockout Mausmodells (Mx-Cre/Met fl/fl) die Funktion von Met in 
DCs unter steady-state Bedingungen und bei Entzündung untersucht. Dabei standen 
die zwei Hauptpopulationen von DCs der Haut, dermale DCs (dDCs) und epidermale 
Langerhans Zellen (Langerhans cells, LCs) im Mittelpunkt. Verschiedene DC-
Subpopulationen, einschließlich dDCs und LCs, wiesen in vivo in den peripheren 
und lymphatischen Organen unter steady-state Bedingungen eine unterschiedliche 
Expression von Met auf. Die Aktivierung der dDCs/LCs bei einer Entzündung 
induzierte sowohl in vitro als auch in vivo die erhöhte Expression von Met auf diesen 
Zellen. Dermale DCs zeigten eine höhere Met-Expression und damit einhergehend 
eine schnellere Migrationskinetik zu den ableitenden Lymphknoten als LCs. Die 
Blockierung des Met-Signalweges, sowohl genetisch (im Met knockout Modell) als 
auch pharmakologisch (mittels Met-spezifischem Kinaseinhibitor), führte zum Verlust 
der Motilität von dDCs und LCs. Als Folge konnten dDCs und LCs nicht mehr 
mobilisiert werden und aus der Haut auswandern. Im Modell der 
Kontakthypersensitivität wurde dadurch keine Immunreaktion mehr ausgelöst. Die 
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Regulation der Proteaseaktivität von Matrixmetalloproteinasen durch Met wurde als 
beteiligter Mechanismus identifiziert. 
Zusammengefasst zeigen die Ergebnisse dieser Arbeit, dass Met eine 
entscheidende Funktion bei der Mobilisierung von DCs der Haut hat und somit zur 
Erhaltung der Immunität beiträgt. Damit eröffnen sich neue Ansätze zur Behandlung 
von Autoimmunerkrankungen der Haut. 
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ABSTRACT 
 
Dendritic cells (DCs) are the major sentinels of immune surveillance system and a 
key link between innate and adaptive immunity by triggering T-cell specific immune 
responses. Thereby, the migratory properties of DCs are crucial for their immune 
function.   
Met is a receptor tyrosine kinase and the receptor for scatter factor (SF), also known 
as hepatocyte growth factor (HGF). Met signalling exhibits mitogenic, morphogenic 
and motogenic activity of various cells e.g. during embryonic development and 
wound healing. 
The functional expression of SF receptor/Met in skin DCs has been already shown. 
In this thesis, a detailed analysis of Met function in two major DC subpopulations in 
skin, dermal DCs (dDCs) and Langerhans cells (LCs), under steady-state and 
inflammatory conditions is presented by employing a conditional Met KO mouse 
model (Mx-Cre/Met fl/fl). In vivo, a distinct pattern of Met surface expression was 
found in different DC subpopulations, including dDCs and LCs in peripheral and 
lymphoid organs in steady-state. Activation of dDCs/LCs upon inflammation 
efficiently induced expression of Met both in vitro and in vivo. Dermal DC showed 
higher Met expression than LC and faster migration kinetics towards draining lymph 
nodes (LNs). Finally, genetic and pharmacological deficiency of Met severely 
impaired motility of dDCs/LCs resulting in failed mobilization of dDCs/LCs from skin 
and thus in disability of dDCs/LCs to mount an immune response in contact 
hypersensitivity reactions. Here, the regulation of matrix metalloproteinase activity by 
Met signalling was identified as one potential mechanism. 
Taken together, the data of this work demonstrate an essential function of Met for 
DC mobilization contributing to skin immunity and suggest new ways of treating 
autoimmune skin diseases.  
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1. INTRODUCTION 
1.1. Dendritic cells (DCs) 
Dendritic cells (DCs) are a heterogeneous set of professional and multifunctional 
antigen-presenting cells, which possess a unique life cycle, differentiation pathways, 
and functions (Merad and Manz, 2009; Shortman and Naik, 2007; Steinman and 
Banchereau, 2007). They originate from bone marrow (BM) haematopoietic stem 
cells or from local progenitors of BM origin. DCs are scattered in lymphoid and in 
non-lymphoid organs throughout the body, and they are, as sentinels of the immune 
system, highly specialized on pathogen recognition, uptake, processing, and 
presentation, and thus induction of appropriate immune responses.  
  
1.1.1. DCs in the immune system 
DCs are the most potent antigen-presenting cells that play a crucial role in the 
induction of primary immune responses. They are inducers of both innate and 
adaptive immune responses.  
As immature DCs, they defend host against pathogens using their innate immune 
defence mechanisms and physiological properties, such as:  
(a) ability to rapidly recognize pathogens via pathogen recognition receptors (PRRs),  
(b) ability to capture foreign and endogenous (e.g. apoptotic bodies) materials via 
different uptake mechanisms including (1) macropinocytosis, (2) receptor-mediated 
endocytosis through Fcγ and Fcε receptors (Maurer et al., 1996; Sallusto and 
Lanzavecchia, 1994) or (3) mannose (Sallusto et al., 1995) and C-type lectin 
receptors (Jiang et al., 1995), (4) engulfment of apoptotic bodies through vitronectin 
receptors (Albert et al., 1998; Rubartelli et al., 1997), and (5) phagocytosis,  
(c) ability to signal the presence of danger to other immune cells using cytokines and 
other soluble factors, such as interferons (IFNs), tumour necrosis factor (TNF)-α, 
interleukin (IL)-6, and IL12,  
(d) ability to produce toxic defence molecules, e.g. nitric oxide for host resistance to 
intracellular infections  (Serbina et al., 2003).  
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Furthermore, DCs are considered as the major link between innate and adaptive 
immunity due to the fact that, when they mature, they present antigens on their major 
histocompatibility complexes (MHC) of class I and class II to naïve and memory T 
cells in the T-cell areas of secondary lymphoid organs, initiating adaptive immune 
responses. While MHC class I is expressed by all cell types of the body, which are 
all potentially exposed to viral infections, except red blood cells, MHC class II 
expression is restricted only to some cell types of the immune system, known as 
antigen-presenting cells, which includes DCs, macrophages, and B cells. MHC class 
II on the surface is loaded with soluble antigens taken up via macropinocytosis, 
receptor-mediated endocytosis, or phagocytosis and captured in endosomes to 
present to CD4+ T cells. Like other cells expressing MHC class I, DCs present 
cytosolic peptides originating from self-antigens and intracellular pathogens like viral 
proteins to T cells on MHC class I molecules. Interestingly, DCs exhibit the unique 
property to load MHC class I antigens with peptides of phagocytosed antigens or 
immune complexes to present antigens to naïve T cells and generate CD8+ 
cytotoxic T cells via a phenomenon known as cross-presentation (Banchereau et al., 
2000).  
Besides activation of T cell-specific immune responses, DCs are further known to 
contribute to humoral immune responses by capturing and transferring antigens to B 
cell receptors as well as by providing signalling to B cells through direct cellular 
interactions and soluble factors (Bell et al., 1999). 
DCs contribute also to tolerance. In thymus, tolerogenic DCs present antigen to 
alloreactive and autoreactive T cells, which leads to T-cell death, T-cell anergy or 
regulatory T-cell expansion or generation. This immune-modulatory feature of DCs 
raises hope for effective treatment of graft rejection after organ transplantation and 
Graft-versus-host disease (GVHD), which occurs in allogenic haematopoietic stem 
cell transplantation for the treatment of leukemia and other blood malignancies, 
where donor-derived T cells are activated against the host (Morelli and Thomson, 
2007).  
DCs have an important role to maintain the balance between immunity and tolerance, 
which is essential to develop effective immune response against infectious agents 
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while limiting collateral damage to self-tissue. Mediating these two opposing tasks 
fundamentally relies on their appropriate differentiation, maturation and migration.  
For all these reasons, DCs are a particularly attractive target for the development of 
therapeutic approaches in various pathological situations such as cancer, infectious 
and autoimmune diseases and in organ transplantation. Their strong property of 
initiating immunogenic T cell responses implicates their high potential for cancer 
therapies and therapies against infectious diseases. For example, DC vaccines are 
considered as a promising strategy to activate cytotoxic T cells against tumours. In 
this case, tumour antigen-bearing DCs are manipulated to induce immunogenicity, 
but not tolerance (Morelli and Thomson, 2007). For years, numerous studies have 
addressed to manipulate DCs to promote immunogenicity or tolerance for 
appropriate purposes  
 
1.1.2. DC-related diseases 
DCs have an exceptional role in the regulation of immunity and tolerance. Therefore, 
loss of proper DC function will destabilize the immune function of the body, resulting 
in insufficient protection of the body against infections (von Bernuth et al., 2008) or in 
susceptibility to auto-immune diseases (King et al., 2010; Yan et al., 2010). And 
excessive DC function and activation would lead to tissue damage during normal 
protective responses against infections, which is the underlying cause of immune-
mediated inflammatory diseases. Thus, aberrant function of DCs can play major or 
even key roles in many diseases.  
Dysfunction of DCs is closely related to the development of different immune 
diseases, since the potent regulatory function of DCs orchestrates development of 
protective T helper (Th) cell subsets, namely Th1, Th2, and Th17 cells. Common 
diseases caused by the dysfunction of DCs are auto-immune, allergic, and chronic 
inflammatory diseases (Table 1).  
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Type of 
response 
Immunological consequences Nature of diseases 
Th1 Macrophage-mediated Inflammation,  
injurious antibodies 
Auto-immune diseases 
Th2 IgE + eosinophil-mediated inflammation Allergic diseases 
Th17 Acute and chronic inflammation  Chronic inflammatory 
diseases 
Table 1 Different types of DC-mediated Th cell responses and immunological diseases 
caused by aberrant function of DCs The nature of the disease is determined by the 
dominating type of immune response. 
 
Auto-immune diseases are characterized as inflammatory responses to self-antigens. 
Such inflammatory responses involve different immune cells and results from the 
activity of Th1 T cells stimulated by inflammatory DCs (Zaba et al., 2009). The auto-
immune disease systemic lupus erythematosus (SLE) is a well known prototypic 
immune complex-mediated auto-immune disease. In SLE, immune complexes 
consist of auto-antibodies and self-nucleic acids of nucleoproteins (Jordan, 1989). 
Self-nucleic acids in immune complexes continuously trigger the production of type I 
IFN by pDCs, and this is considered as a critical event in the initiation of SLE 
(Ronnblom and Alm, 2003). 
Allergic diseases, such as atopic dermatitis, asthma, and contact hypersensitivity 
result from dysfunctional Th2 response mediated by DCs (Moser and Murphy, 2000). 
Contact hypersensitivity is a delayed-type (Type IV) hypersensitivity reaction 
mediated by antigen-specific effector T cells primed by allergen-laden DCs in 
draining lymph nodes (Grabbe and Schwarz, 1998).  
Chronic diseases based on Th17 response are rheumatoid arthritis, auto-immune 
hepatitis, multiple sclerosis, juvenile diabetis, Crohn’s disease and the chronic auto-
inflammatory skin disorder psorias. They are immune-mediated inflammatory 
diseases with prominent inflammation, caused by failure of tolerance or regulation 
(Harrington et al., 2005; Stockinger and Veldhoen, 2007). They may result from 
activation of auto-reactive T cells through abnormal presentation of self-antigens by 
DCs (Dhodapkar et al., 2008).   
 
INTRODUCTION 5 
 
1.1.3. DC subpopulations 
The heterogeneous pool of DCs consists of various subpopulations with distinct 
developmental backgrounds and differs in their anatomic distribution, surface and 
intracellular phenotypic markers (such as PRRs), immunological function (e.g. ability 
to influence T-cell fate), and genetic programme (Naik, 2008; Zenke and Hieronymus, 
2006). All DCs express the integrin CD11c and MHC class II molecules, albeit at 
different levels. DCs can be separated into a number of different subpopulations 
based on selective expression of subpopulation-specific markers including CD8α, 
CD4, CD11b, Langerin, and PDCA-1. Different DC subpopulations arise from distinct 
developmental pathways. However, differentiation programmes, and homeostatic 
regulation of each subpopulation have remained elusive (Ginhoux et al., 2009; Liu et 
al., 2007; Merad and Manz, 2009). Significant progress in shedding light on details of 
DC development has been made by a number of recently developed techniques 
such as knockout mouse models, adoptive transfer of cells, in vivo 5-bromo-2-
deoxyuridine (BrDU) staining and parabiosis experiments. For example, parabiosis 
experiments have facilitated to study circulating DCs and DC progenitors. Results of 
such experiments suggested that DCs can be derived not only from self-renewing 
progenitors in BM, but also in other tissues (Liu et al., 2009; Merad et al., 2002) 
 
1.1.3.1. In vivo DC subpopulations 
DC subpopulations have been classified according to their different features, such as 
surface phenotype, function, and anatomic localization. Based on anatomic 
localization, DCs can be subdivided in three different categories, which are all found 
together in secondary lymphoid organs: (1) Non-lymphoid tissue-resident DCs, (2) 
lymphoid tissue-resident DCs, and (3) blood-circulating DCs.  
DC subpopulations of the first two categories can be grouped together as so-called 
“conventional DCs (cDC)”. In cDCs, MHC class II traffic and presentation are tightly 
controlled along their maturation in order to optimize antigen presentation. The 
category of blood-circulating DCs comprises plasmacytoid DCs (pDCs) and a minor 
part of DCs that phenotypically and functionally resemble cDCs.  
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The first category of non-lymphoid tissue-resident DCs comprises the best-studied 
prototype of DCs. These are the DCs that take up antigen from the periphery as 
immune sentinels and present the processed antigen to T cells to trigger antigen-
specific immune responses. They are also called “migratory DCs”, because they 
migrate upon antigen uptake from the site of their steady-steady location, such as 
gut, lung, and skin, to the site of antigen presentation in the secondary lymphatic 
organs. In steady-state tissues, DCs express an intermediate level of MHC class II. 
In lymph nodes, activated migratory DCs can be detected as MHC class II-high 
B220/CD45RA- CD205/DEC205+ population. Non-lymphoid tissue-resident DCs are 
a heterogeneous pool. Constitutive migration of steady-state non-lymphoid tissue-
resident DCs towards the draining lymph node (LN) has been also reported, but this 
process only occurs at a low rate. They remain semi-mature without up-regulation of 
co-stimulatory molecules (Jakubzick et al., 2008a; Ohl et al., 2004). Two main DC 
populations can be distinguished according to the expression of CD11b and CD103. 
The first population is characterized by a high expression of the myeloid lineage 
marker CD11b and by lack of the integrin molecule CD103, whereas the second DC 
subpopulation is recently characterized by the expression of CD103 in combination 
with a low or no expression of CD11b. The existence of two distinct populations was 
shown in different organs such as skin dermis, lung, liver, kidney, pancreas, and 
intestine (Ginhoux et al., 2009; Varol et al., 2009). Skin epidermis contains 
Langerhans cell (LC) instead of these two DC subpopulations. LCs comprise an 
unique DC subpopulation, which will be explained in detail in the following 
paragraphs. Lamina propria has also a unique DC subpopulation with a CD11b+ 
CD103+ double positive phenotype (Ginhoux et al., 2009; Varol et al., 2009). These 
different non-lymphoid tissue-resident DC subpopulations are supposed to have 
different origins. For the development of CD11b+ CD103- DCs, Fms-like tyrosine 
kinase-3 (Flt3) and M-CSFR signalling have been shown to be important (Ginhoux et 
al., 2009). Unlike CD103+ populations, CD11b+ CD103- DCs also express some 
macrophage markers such as F4/80, CX3CR1, and Sirp-α. Certain CD11b+ CD103- 
DCs have been shown to share same precursors with tissue-resident macrophages, 
namely the Ly-6C- CX3CR1-high CCR2-low CD62L- monocytes (Jakubzick et al., 
2008b). However, the exact contribution of monocytes to non-lymphoid tissue-
resident DCs remains still elusive. In most tissues, the relative number of CD103+ 
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DCs are lower than that of CD11b+ DCs (Helft et al., 2010). CD103+ CD11b- DCs 
exclusively originate from a DC precursor (pre-cDCs), which also give rise to 
lymphoid tissue-resident conventional DCs. Development of CD103+ DCs from pre-
cDCs depend on Flt3 and the transcription factors Id2 (inhibitor of 
differentiation/DNA-binding protein 2) and IFN regulatory protein 8 (IRF8) (Ginhoux 
et al., 2009). They are supposed to play an important role in cross-presentation 
(Henri et al., 2010) and in induction of immune tolerance (Coombes et al., 2007; 
Johansson-Lindbom et al., 2005; Sun et al., 2007). Based on development and 
function, CD103+ DCs in non-lymphoid tissue resemble CD8α+ DC subpopulation of 
lymphoid tissue-resident DCs (see below) (Bedoui et al., 2009; Ginhoux et al., 2009).  
Under inflammatory conditions, the development of DCs has been shown differently 
regulated in comparison to steady-state conditions. During inflammation, pluripotent 
hematopoietic stem and progenitor cells (Massberg et al., 2007), lineage-committed 
BM-derived DC precursors (Fogg et al., 2006; Naik et al., 2007), and blood-
circulating monocytes (Gordon and Taylor, 2005) can be additionally recruited from 
blood to peripheral tissue and differentiate to DCs of inflammatory phenotype. For 
example, Ly-6C-high CX3CR1-low CCR2-high CD62L+ (Gr-1-high) monocytes were 
identified as LC precursors of the inflamed skin (Ginhoux et al., 2006) and as 
precursors of TNF-α and inducible nitic oxide synthase (iNOS) producing DCs (Tip 
DCs) (Naik, 2008). Gr-1-high monocytes also give rise to other non-lymphoid tissue-
resident DCs (Jakubzick et al., 2008b; Le Borgne et al., 2006; Leon et al., 2007).  
Lymphoid tissue-resident DCs belong to the second category, which reside in the 
secondary lymphatic organs throughout their life span. They arise from pre-cDC 
precursor that entered lymphoid organs and develop in a Flt3-dependent manner 
(Liu et al., 2009). In this category, we distinguish two major DC subpopulations: 
CD8α+ CD11b- DCs (CD8α+ DC) and CD8α- CD11b+ DCs (CD8α- DC). There are 
more molecules differentially expressed on CD8α+ and CD8α- mouse DC 
subpopulations, e.g. CD205, CD24 and CD36 are highly expressed on CD8α+ DCs, 
whereas Dcir2/33D1 is expressed on CD8α- DCs. While the precise function of 
CD8α- DCs is still unknown, CD8α+ DCs have a unique ability to cross-present 
exogenous antigens. The thymus contains various residential DC subpopulations 
consisting of a major population of CD8α+ cells and a minor population of CD8α- 
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Sirp-α+ cells. Thymic DCs are important for the negative selection of T cells (Brocker 
et al., 1997). CD8α+ DCs are supposed to differentiate from early thymocyte 
progenitors in contrast to CD8α- Sirp-α+ DCs (Wu and Shortman, 2005).  
In the LN, there are also DCs that have migrated from the periphery towards lymph 
nodes. But, lymph-migrating, non-lymphoid tissue-derived DCs are minor 
constituents with the steady-state LN (Jakubzick et al., 2008a), and they can be 
distinguished by their immature phenotype and property of antigen uptake and 
processing (Wilson et al., 2003). Lymphoid tissue-resident DCs certainly exert other 
immune functions than DCs from other categories. They capture and present 
antigens within the lymphoid organ. 
The third category of DCs consists of blood-circulating DCs. The majority of blood-
circulating MHCII+ CD11c+ DCs are pDCs, but also a low number of cDCs and DC 
progenitors can be found (del Hoyo et al., 2002). Differentiated DCs are considered 
as a mixture of newly generated cells from the BM and DCs from peripheral tissue 
that have re-entered the circulation (Alvarez et al., 2008). Both cell types together 
represent about 0.2 - 0.4% of all peripheral blood mononuclear cells (Krug et al., 
2001). Mouse pDCs express MHC class II and an intermediate level of CD11c. They 
are further characterised by expression of the lineage markers B220, Gr-1/Ly6C, 
PDCA-1 and siglec (sialic acid binding Ig-like lectin)-H. Majority of pDCs circulate in 
blood, but low numbers are also found in steady-state in BM, spleen, thymus, LN, 
and the liver, but rarely in other peripheral tissues. pDCs play a key role in anti-viral 
immunity through their capacity to produce large amounts of type I IFN. Depending 
on the stimuli, pDCs have been shown to differentiate into DCs of conventional 
phenotype, up-regulating MHC class I and II, as well as co-stimulatory molecules 
(Liou et al., 2008; Zuniga et al., 2004). However, their antigen presentation capacity 
remains unclear because of the lack of characterization of antigen processing and 
presentation pathways.  
 
1.1.3.2. DC development 
There is a notable variation among DC subpopulations regarding their origins and 
developmental backgrounds. DC differentiation has shown to be more complex than 
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originally assumed (Merad and Manz, 2009; Naik et al., 2007; Zenke and 
Hieronymus, 2006). In homeostasis, DCs except LCs have relatively short lifespan in 
comparison to other cell types, ranging from 24 hours to 4 weeks (Merad and Manz, 
2009). DCs are steadily renewed and replaced. 
 
 Figure 1  Differentiation of DCs and macrophages in mice. Adapted from Geissmann et 
al. (Geissmann et al., 2010) 
 
DCs originate from self-renewing haematopoietic stem cells (HSCs) constituting a 
small fraction in the adult BM (Figure 1). The self-renewing HSCs produce non self-
renewing multipotent progenitors, which give rise to myeloid progenitors (MPs; also 
known as common myeloid progenitors/CMPs) and lymphoid progenitors (LPs; 
common lymphoid progenitors/CLPs) with gradually restricted developmental options 
that finally differentiate into mature, mostly non-dividing cells. The conception of DC 
development has been steadily up for a debate. In the past, there was a clear 
classification of DCs into a lymphoid and into a myeloid progeny (Ardavin et al., 1993; 
Wu et al., 1998). The current notion is that lymphoid and myeloid progenitors have 
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higher plasticity for the DC development. MPs are known to give rise to monocytes 
being precursors of inflammatory and non-lymphoid tissue-resident DC 
subpopulations as well as common DC precursors (CDPs) being precursors of 
lymphoid tissue-resident DC population (Geissmann et al., 2010). 
Some growth factors and cytokines have been revealed to be essential for DC 
development in vivo and in vitro. Key cytokines that have been identified are 
granulocyte-macrophage colony stimulating factor (GM-CSF), Flt3-ligand, and 
macrophage colony stimulating factor (M-CSF). Transforming growth factor (TGF)-β1 
was found to be indispensable in LC development. IL-4, TNF-α, lymphotoxin-β, and 
G-CSF are also involved in DC development, but with minor impact (Merad and 
Manz, 2009; Schmid et al., 2010).  
Among all DC-poietins, Flt3-ligand is the most important in steady state. Flt3-ligand 
is expressed by multiple tissue stroma cells and activated T cells. In vivo, Flt3-ligand 
expression is constitutively present and is increased upon inflammation. Flt3-ligand 
has been shown as sufficient and essential for the development of lymphoid tissue-
resident DCs and pDCs, as evidenced by Flt3-ligand-deficient mice or mice treated 
with Flt3 tyrosine inhibitor demonstrating a prominent reduction of these DC 
subpopulations (McKenna et al., 2000; Tussiwand et al., 2005). Still, DC 
development is not completely abolished in these mouse models. In contrast, in vivo 
injection or conditional expression of Flt3-ligand resulted in massive expansion of 
pDCs and all types of cDCs (Karsunky et al., 2003; Maraskovsky et al., 1996). 
Homeostatic and inflammatory LC development is Flt3-independent, and CD11b-
high CD103+ DC subpopulation in the lamina propria do not need Flt3 stimulation 
during development (Merad and Manz, 2009). 
GM-CSF is an important cytokine for DC development from haematopoietic 
progenitors and monocytes. GM-CSF was the first cytokine discovered that 
efficiently supported DC differentiation in vitro (Inaba et al., 1992; Sallusto and 
Lanzavecchia, 1994). GM-CSF is expressed by tissue stroma cells, activated T cells 
and NK cells. While in steady state GM-CSF is not present in serum, GM-CSF 
expression is detected under inflammatory conditions. First, GM-CSF was thought to 
be not essential for the development of steady-state DCs, based on the observation 
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that steady-state DC development is normal in GM-CSF- or GM-CSF receptor-
deficient mice. In vivo injection or overexpression of GM-CSF resulted only in 
moderate changes in steady-state DC numbers. In contrast, treatment with stabilized 
GM-CSF with extended half-life or injection of GM-CSF expressing adenovirus led to 
expansion of inflammatory DCs. In human, injection of GM-CSF is used for 
generation of DCs at disease site (Merad and Manz, 2009; Vremec et al., 1997). 
However, recent studies have shown that the absence of the GM-CSF receptor 
compromises the development of CD11b+ DCs in the skin and in the lamina propria 
(Bogunovic et al., 2009; King et al., 2010; Kingston et al., 2009; Schmid et al., 2010; 
Varol et al., 2009). 
M-CSF/CSF-1 is an important cytokine for macrophage and monocyte development. 
M-CSF is expressed by endothelia, stroma cells, osteoblasts, and macrophages. 
Like Flt3-ligand, M-CSF is constitutively expressed and is up-regulated upon 
inflammation. M-CSF-deficient mice demonstrate impaired monocyte development 
(Dai et al., 2002) and homeostatic development of LCs (Ginhoux et al., 2006) In vivo 
injection of M-CSF resulted in expansion of lymphoid tissue-resident DCs (Merad 
and Manz, 2009). 
TGF-β is important for DC development in vitro and in vivo. In vitro, CD34+ 
hematopoietic stem cells were shown to give rise to cells with a LC phenotype in 
presence of TGF- β (Strobl et al., 1996). Gene deletion of autocrine and paracrine 
TGF-β in mice resulted in lack of LCs (Kaplan et al., 2007). A large amount of  TGF-
β is produced by keratinocytes in the epidermis (Merad and Manz, 2009).  
 
1.1.3.3. In vitro generated DCs 
Like in vivo, DCs can be generated in vitro from various sources, such as mouse BM 
(Inaba et al., 1992), purified human HSCs from cord blood (Santiago-Schwarz et al., 
1992) or BM (Reid et al., 1992), and blood monocytes (Bender et al., 1996; Romani 
et al., 1996). They can differentiate into DCs in presence of the DC-poietins 
described in the previous paragraphs, which are GM-CSF (Inaba et al., 1992), Flt3-
ligand (Brasel et al., 2000), and M-CSF (Fancke et al., 2008). All of these factors are 
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effective as single cytokine. Characteristics of in vitro generated DCs differ according 
to the cytokine provided.  
In vitro DC development mediated by GM-CSF results in generation of DCs of 
myeloid lineage that comprise CD24-high CD11b-low and CD24-low CD11b-high 
populations (Xu et al., 2007). In human system, GM-CSF allows differentiation of 
CD34+ HSC and human monocytes into DC (Bender et al., 1996; Romani et al., 
1996). Furthermore, GM-CSF is able to differentiate Gr1-high monocytes to DCs. In 
conjunction with their functional features, e.g. high granularity and production of 
inflammatory DC-specific mediators, such as TNF-α and NO, GM-CSF-derived DCs 
in vitro are thought to be the functional and phenotypical equivalents of the TNF-α 
and iNOS producing DCs in vivo (Xu et al., 2007). 
By stimulating murine BM cells with Flt3-ligand, functional and phenotypical 
equivalents of steady-state lymphoid tissue-resident DC subpopulations and pDCs 
can be generated: CD8α- cDCs, CD8α-like cDCs and pDCs. Both CD8α- and CD8α-
like subpopulations do not express the surface marker CD8α, but can be 
distinguished by the expression level of CD24. CD8α-like DCs are a CD24-high 
population and express CD8α on the transcriptional level in vitro. They are supposed 
to up-regulate surface expression of CD8α in vivo when transferred into mice (Naik 
et al., 2005). The development of an Flt3-ligand culture system with BM cells has led 
to the straightforward generation of large numbers of pDCs that resemble their in 
vivo steady-state counterparts (Fancke et al., 2008; Xu et al., 2007). 
M-CSF, originally associated with macrophage and monocyte development, is 
recently described to derive the set of both DC subpopulations pDCs and cDCs, 
which resemble DC subpopulations generated with Flt3-ligand. Unlike in Flt3-ligand 
culture, macrophages and monocytes development accompanies DC differentiation 
with M-CSF (Fancke et al., 2008). 
In addition, there is a limited number of studies with human cells showing SF/HGF as 
a factor that has a potential to induce DC differentiation like other DC-poietins 
mentioned before (Zou and Tam, 2002). DCs or DC-like cells were generated with 
SF/HGF from human CD34+ BM HSCs (Ovali et al., 2000) and also from peripheral 
blood monocytes (Rutella et al., 2006a; Sonmez et al., 2007). SF/HGF-derived DC-
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like cells have been supposed to have tolerogenic properties (Rutella et al., 2006a; 
Rutella et al., 2006b). Such SF/HGF-supported DC development systems using 
mouse cells have not been yet reported.  
 
1.1.4. DCs in skin immunity 
In the epidermis and the dermis, there are different DC subpopulations. DC 
subpopulations are clearly separated according to their compartments.  
Phenotypically and developmentally, LCs are a unique subpopulation of immature 
DCs in the epidermis. LCs represent the first critical immunologic barrier to the 
external environment. Mouse LCs are characterized by expression of surface 
markers CD11c, CD11b, Langerin/CD207, and EpCAM and by a specific type of 
intracytoplasmic organelle known as the Birbeck granule. In steady state, they arise 
from radio-resistant local precursors. Under inflammatory conditions, they can 
develop from blood-circulating Gr1-high monocytes (Ginhoux et al., 2006). Based on 
previous studies, mainly performed in vitro, LCs were considered to bear the typical 
immunogenic DC function after antigen uptake and presentation (LC paradigm). But 
evidences have been accumulating that LCs do not play an important role in 
induction of immune responses as direct antigen-presenting cells, but in mediating 
and maintaining peripheral tolerance, as demonstrated in contact hypersensitivity 
studies (Fukunaga et al., 2008; Kaplan et al., 2005; Kissenpfennig et al., 2005; 
Merad et al., 2008; Romani et al., 2010). Some results from these studies are 
controversial. In several studies, LC-depleted mice showed rather an enhancement 
than a reduction of contact hypersensitivity or no difference to LC-bearing mice 
(Kaplan et al., 2005; Romani et al., 2010).  Diseases known to be associated with 
LCs are Langerhans cell histocytosis characterized by heterogeneous lesions 
containing LCs and lymphocytes in skin, bone or other tissues of the body 
(Weitzman and Egeler, 2008), and Langerhans cell sarcoma (Sumida et al., 2008). 
An inflammatory DC subpopulation in the epidermis was found as inflammatory 
dendritic epidermal cells (IDECs), which can be distinguished from steady-state LCs 
by the macrophage mannose receptor CD206, found in the inflamed epidermis of 
atopic dermatitis patients (Wollenberg et al., 2002). 
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Interstitial DCs of the CD11c+ CD11b-high phenotype constitute the major DC 
subpopulation in the dermis. CD11c+ CD11b+ dermal DCs develop independently of 
Id2 and IRF8, but dependently on Flt3-ligand and M-CSF (Ginhoux et al., 2009). 
They bear prototypical features of non-lymphoid tissue-derived CD11b-high CD103- 
DCs as described above (see 1.1.3.1). Besides the major DC subpopulation in the 
dermis, a minor population of DCs has been described as Langerin+ dermal DCs 
(Bursch et al., 2007; Ginhoux et al., 2007; Merad et al., 2008; Poulin et al., 2007), 
which was characterized by CD103 expression. Langerin+ dermal DCs are the only 
DC subpopulation expressing CD103, thus can be distinguished from LCs 
transmigrating the dermis. As mentioned previously, CD103+ DCs arise from pre-
DCs under the control of Flt3-ligand, Id2 and IRF8 like lymphoid tissue-resident 
CD8α+ DCs (Ginhoux et al., 2009). They also resemble CD8α+ DCs functionally. 
Among all skin DC subpopulations, CD103+ DCs are supposed to be the most 
efficient subpopulation in processing viral antigens into the MHC I pathway, 
potentially through cross-presentation (Bedoui et al., 2009).  
Further surface markers, which are differentially expressed on LCs and dermal DCs 
are the C-type lectins CD209/DC-SIGN and CD205/DEC205. Only dermal DCs 
express CD209, while they express CD205 at lower levels than LCs (Romani et al., 
2006). 
 
1.1.5. DC trafficking in skin 
DCs possess an exceptional migratory capacity that is critical for their immune 
function. These motile properties allow DCs to populate and functionally integrate 
into peripheral tissues as immature DCs specialized in pathogen recognition. In 
steady state, they remain in the tissue. Thus, each tissue maintains a characteristic 
number of tissue-resident DCs. But, in case of injury or infection, further DCs can be 
additionally recruited. Following antigen capture, DCs are activated and migrate via 
lymphatic vessels to the draining LN to activate naïve T cells in T-cell areas of 
secondary lymphoid organs and prime immune responses. Therefore, DCs have to 
up-regulate chemokine receptors and co-stimulatory molecules before homing to 
secondary lymphoid organs. Migration of DCs to secondary lymphoid organs also 
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plays a crucial role in the initiation of immune responses. During DC life cycle, 
migration and homing are tightly regulated e.g. by the specific expression of 
chemokines and chemokine receptors and other mobilizing factors, adhesion 
molecules and homing receptors to ensure the selective positioning of DCs to their 
specific sites of action. Steady-state DCs also are supposed to spontaneously traffic 
to the LN at very low numbers, as evidenced by the presence of steady-state DCs in 
afferent lymph and the quantitative estimation of skin DCs in the skin draining LN 
(Brand et al., 1992; Bujdoso et al., 1989; Tomura et al., 2008). The steady-state 
migration may serve to tolerate T cells against self and non-dangerous antigens 
(Steinman et al., 2003). The mechanism that triggers steady-state DC migration 
remains elusive.  
The pattern of DC migration differs in various DC subpopulations (Liu, 2001). 
Referring to the migration pattern, two groups of migratory DCs can be distinguished. 
The first group comprises non-lymphoid tissue-resident DCs. They can be referred to 
DCs that follow a classical pattern of DC migration. This pattern includes sensing 
and following soluble and surface-bound chemoattractant cues through the 
interstitium and proceeding into the LN through afferent lymphatics. DC migration 
towards the LN requires a series of steps, comprising an initiation step with (1) 
mobilization and (2) detachment from surrounding tissue and a migration step with (1) 
interstitial migration, (2) entry into the afferent lymphatics, and (3) transit via lymph 
(Alvarez et al., 2008). The second group consists of pDCs circulating in the blood 
vessels. pDCs are also found to be recruited to inflamed tissues, such as lupus 
erythematosus lesions (Farkas et al., 2001), psoriatic skin (Nestle et al., 2005), and 
the nasal mucosa (Jahnsen et al., 2000), but the migration mechanisms of pDCs in 
the intestitium are quite unknown. Frequently, pDCs are supposed to enter the LN 
directly from the blood by extravasating across high endothelial venules, but may 
occasionally migrate via afferent lymphatics (Pascale et al., 2008).  
 
1.1.5.1. DC recruitment and DC progenitor migration to skin 
Under steady state, LCs are supposed to develop from radio-resistant local 
precursors (Merad et al., 2002). Dermal DCs have shorter turnover and develop from 
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BM-derived precursor. The interaction of chemokines and chemokine receptors have 
been shown to be indispensable for the migration of LCs and DCs (Sozzani, 2005). 
However, most studies on DC recruitment and migration of DC precursor cells into 
skin have been performed under inflammatory conditions. Gr-1-high monocytes are 
recruited to inflammatory tissues, such as skin, lung and interstitial lamina propria, by 
the pro-inflammatory chemokine CCL2/MCP-1 and CCL7/MCP-3, which are sensed 
via CCR2. At the site of inflammation, they give rise to cDCs (Auffray et al., 2007; 
Geissmann et al., 2003; Ginhoux et al., 2006; Landsman et al., 2007; Merad et al., 
2002; Varol et al., 2007).  For LC reconstitution, the CCL20 receptor CCR6 is 
involved in recruitment of blood-born LC progenitors (Merad et al., 2004). CCL20 is 
expressed in inflamed tissues, and, especially in skin, produced by inflamed 
keratinocytes (Charbonnier et al., 1999). Its receptor CCR6 is also known to be a 
receptor for the innate immunity defense peptides, namely defensins, and is 
responsible for β-defensin-derived chemotaxis of DCs (Yang et al., 2002a).  
Also non-chemokine peptides and their receptors are involved in recruitment of 
immature skin DCs to the site of inflammation. The non-chemokine Chemerin 
activated by serine proteases in inflamed skin is a chemoattractant for both blood-
circulating cDCs and pDCs and signals via the chemokine-like receptor CMKLR 
(Vermi et al., 2005; Zabel et al., 2005). FRL and FPRL2 is other non-chemokine 
receptors expressed by immature DCs. FRL and FPRL2 are receptors for the strong 
chemoattractants N-formylmethionyl-lencyl-Phenylalanin (fMLP) and  F2L and 
regulate DC trafficking during antigen uptake and processing in the periphery (Yang 
et al., 2002b). 
The ADP-ribosyl cyclase CD38 has been also identified to be important for the 
migration of DC precursors from blood to the peripheral sites (Partida-Sanchez et al., 
2004). In humans, CD38 is up-regulated during DC maturation (Fedele et al., 2004), 
and controls also the  migration of mature DCs from sites of inflammation to the LN 
(Partida-Sanchez et al., 2004).  
 
1.1.5.2. DC mobilization and detachment in skin 
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DC trafficking can occur in steady state for single cells, but the mechanism is rather 
elusive. A synchronized mass mobilization of DCs is usually linked to inflammation. 
In this case, the mobilization signals conform to inflammatory signals and can be of 
chemical (e.g. contact senstitizers and irritants), physical (e.g. UV irradiation or 
trauma), and biological character (e.g. microbes or tissue necrosis) (Alvarez et al., 
2008).  
Among these inflammatory signals, the most potent mobilization signals are IL-1β 
and TNF-α. They are also involved in the activation of DCs. Contact sensitizers 
induce accumulation of IL-1β and TNF-α in the epidermis (Enk et al., 1993a; Enk et 
al., 1993b). Neutralizing antibodies to IL-1β and TNF-α inhibited contact sensitization 
and LC redistribution (Cumberbatch and Kimber, 1995), whereas dermal injection of 
IL-1β and TNF-α decreased the number of LCs in the epidermis and increased the 
number of DCs in the skin-draining LNs (Cumberbatch et al., 1997b; Cumberbatch et 
al., 1992; Cumberbatch and Kimber, 1992). IL-1β and TNF-α do not stimulate only 
DCs and LCs, but also dermal fibroblasts, which may further contribute to the 
mobilization of DCs and LCs by providing them with additional pro-inflammatory 
signals, such as IL-6 (Saalbach et al., 2010).   
The migration of DCs is regulated by specific cell adhesion molecules, such as 
integrins, on the cell surface. Once receiving a mobilization signal, the DCs have to 
detach from the peripheral tissues, e. g. LCs from neighbouring keratinocytes, and 
migrate through tissues rich in extracellular matrix proteins, such as collagen type I-
IV, fibronectin, and laminin and cross the underlying basement membrane. DCs 
need to interact with different basement membranes and extracellular matrix (ECM) 
components. Maturing DCs activate proteolytic enzymes in membrane-bound and 
secreted forms to degrade the basement membranes and ECM barriers (Alvarez et 
al., 2008). Among these, matrix metalloproteinase (MMP)-9 and -2 are found to be 
critical for the migration of DCs within dermal meshwork. Skin-emigrating DCs 
express the membrane-bound form of MMP-9 and MMP-2 in contrast to monocyte-
derived DCs. The importance of MMP-9 was emphasized using MMP-9-deficient 
mice, in which LC mobilization from epidermis was strikingly reduced (Kobayashi et 
al., 1999; Ratzinger et al., 2002). Interestingly, inflammatory macrophages also 
require MMP-9 activation for migration (Gong et al., 2008). Prostaglandin E2 (PGE2) 
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and IL-6 have been shown to induce MMP-9 activity in DCs (Saalbach et al., 2010; 
Yen et al., 2008). Other proteases are supposed to be involved in different steps of 
DC migration. Membrane type 1 (MT1)-MMP activity on DC podosomes is shown to 
play a role in pericellular proteolysis, and podosomes are disassembled by a 
disintegrin and metalloprotease 17 (ADAM17) (West et al., 2008). Certain MMPs and 
ADAMs (e.g. ADAM-10) are also known to be important to disrupt cell-cell adhesions, 
e.g. E-Cadherin binding (Maretzky et al., 2005). 
PGE2 is a well-known mediator of DC/LC migration, which exerts its physiological 
functions through binding to four receptors, EP1, EP2, EP3, and EP4. Under foreign 
antigen exposure, keratinocytes produce large amount of PGE2. When PGE2 is 
expressed in situ at inflammatory sites, PGE2 initiates skin immune response by 
inducing maturation and migration of cutaneous DCs via EP4 receptor, as evidenced 
by impaired migration of LCs in Ptger4-/- mice lacking EP4 receptor (Kabashima et 
al., 2003).   
Platelet activating factor (PAF) is a prominent chemokine produced at the site of 
inflammation. The role of PAF in the DC mobilization has been suggested by various 
groups, but results are highly controversial. Angeli et al. identified PAF as a negative 
regulator of DC migration using a skin DC migration assay (Angeli et al., 2004), In 
contrast, Fukunage et al. could not find the direct function of PAF on LCs. Using PAF 
receptor KO mouse models, they demonstrated that PAF acts primarily on 
keratinocytes and positively regulates LC mobilization from skin (Fukunaga et al., 
2008).  
 
1.1.5.3. DC migration to secondary lymphoid tissue 
An impressive change in the chemokine receptor inventory is promoted by DC 
activation. Activation of DCs leads to the de novo expression of CCR7, the 
chemokine receptor for the chemokines CCL21 and CCL19. CCR7 is crucial for DC 
migration both under homeostatic and activated conditions (Sallusto et al., 1998; 
Yanagihara et al., 1998). The importance of CCR7 was shown using different mouse 
models. CCR7-deficient mice displayed a severe deficiency of migratory DCs in the 
LN (Forster et al., 1999). CCR7 is required in vivo for DC entry into dermal afferent 
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lymphatics and migration through the lymphatics towards the LN. CCR7 ligands are 
CCL19 and CCL21, which exists as two variants. CCL21-Leu is expressed by 
lymphatic vessels, and CCL21-Ser in the LN. CCL19 is expressed by activated DCs 
and it is unclear whether it is also expressed by lymphatic vessels. A naturally 
occurring mouse mutant plt (paucity of LN T cells), deficient in CCL21-Ser and 
CCL19, shows impaired DC migration to the LN (Chen et al., 2002; Gunn et al., 1999; 
Luther et al., 2000; Vassileva et al., 1999). TREM-2 (triggering receptors expressed 
on myeloid cells-2, (Bouchon et al., 2001)), PGE2 (Scandella et al., 2004), and 
CCL17 (Stutte et al., 2010) have been associated in regulation of CCR7 and thus in 
CCR7-driven DC migration.  
DC migration in the intestitium is associated with the adhesion to endothelial cells 
and the interaction with basement membranes and collagen meshwork. Such 
interactions are regulated by various cell surface adhesion molecules such as 
junctional adhesion molecule (JAM-A), SPARC  and integrins. JAM-A is an adhesion 
molecule expressed at endothelial cell junctions and by leukocytes, and SPARC is a 
calcium-binding matricellular glycoprotein binding extracellular components, Based 
on investigations using knockout mouse models, both factors have been  shown to 
influence DC migration (Cera et al., 2004; Sangaletti et al., 2005).  Thereby, α6 
integrins was early described to be especially required for LC emigration from the 
epidermis (Price et al., 1997). The integrin β2 was supposed to be important, as 
shown by impaired skin DC migration to the skin-draining LN in mice lacking the 
integrin (Xu et al., 2001). However, recent investigations suggest that for DC entry 
into lymphatics and, to a certain grade, also for crawling through the interstitium, 
integrin-mediated adhesive interactions are not necessary (Lammermann et al., 
2008).   
CD44 was also described as important molecule for DC migration, which binds to the 
extracellular matrix component hyaluronate. The CD44 isoforms play an essential 
role in LC and DC functions and are differentially regulated during the LCs 
sensitization, activation, and migration from the skin, and DC adhesion to the 
paracortical T cell zones of peripheral LN (Bell et al., 1999). During their migration to 
peripheral LNs, LCs and DCs up-regulate pan-CD44 epitopes and sequences 
encoded by CD44 variants (Weiss et al., 1997). In CD44-deficient mice, LCs 
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emigrate from the epidermis, but fail to reach the LN after hapten application 
(Mummert et al., 2004). CD44 was also shown to be associated with macrophage 
migration inhibitory factor (MIF) receptor/CD74 (also known as MHC class II-
associated protein invariant chain Ii), which interacts with the motor protein myosin II 
(Naujokas et al., 1993; Shi et al., 2006; Vascotto et al., 2007). Myosin II was 
separately reported to regulate DC migration (Faure-Andre et al., 2008). CD44 also 
interacts with scatter factor receptor/Met in other cellular systems (Matzke et al., 
2007). 
Another known regulators of DC migration are Sphingosine 1-phosphate (S1P) 
receptors, which are expressed on immature and mature murine BM-derived DCs 
(BMDC) in vitro. But, the precise role of S1P receptors is not yet fully understood. In 
mice, S1P receptors are only responsive to their chemoattractant ligand S1P on 
mature DCs, but not on immature DCs (Czeloth et al., 2005; Maeda et al., 2007), 
while in humans they are functional on immature, but not on mature blood-derived 
DCs in vitro (Idzko et al., 2002). 
Recently, Ste20-like kinase SLK/Mst1, was shown to be involved in integrin α4-
dependent and stroma-dependent migration of DCs in the interstitium (Katagiri et al., 
2009). There are also evidences that semaphorins and plexins are potent regulators 
of the actin cytoskeleton in DCs and integrin-mediated adhesion pathways 
suggesting that they are involved in regulation of DC migration (Takamatsu et al., 
2010; Takegahara et al., 2006; Walzer et al., 2005; Wong et al., 2003). 
 
 
1.2. Scatter factor and Met proto-oncogene 
Met is a member of the hepatocyte growth factor receptor (HGFR) subfamily of 
receptor tyrosine kinase (RTK) like Ron/macrophage-stimulating protein (MSP) 
receptor and was originally identified as an oncogene (Park et al., 1986). Met is the 
receptor for hepatocyte growth factor (HGF), also independently identified as scatter 
factor (SF). The ligand was initially described as a mitogenic factor for hepatocytes 
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(Nakamura et al., 1986) and a potent motility factor for epithelial cells (Stoker et al., 
1987).  
Gene inactivation experiments demonstrated that SF/Met signalling is essential for 
embryogenesis. Conventional SF/HGF or Met knockouts have turned out to be 
embryonically lethal (Bladt et al., 1995; Schmidt et al., 1995; Uehara et al., 1995). In 
adults, it plays an important role in wound healing, liver regeneration, and tumour 
progression (Chmielowiec et al., 2007). 
In vivo, Met signalling is indeed strictly regulated by participation of SF 
activators/HGFAs (Kataoka and Kawaguchi, 2010; Miyazawa et al., 1993), SF 
activator inhibitors/HAIs (Kataoka et al., 2001) and MMPs (Daniels et al., 2003) etc. 
Apparently, Nature has developed such a tight regulation of Met activation, obviously 
because abnormal activation of Met signalling leads to momentous consequences 
for the cell function and physiological and immunological regulations. 
 
1.2.1. Met proto-oncogene 
Met is as a single-pass, disulphide-linked α/β heterodimer derived from a common 
precursor by proteolytic processing in the post-Golgi compartment (Trusolino and 
Comoglio, 2002). The α-chain is completely extracellular, whereas the β-chain is a 
transmembrane subunit containing tyrosine kinase activity (Figure 2). Binding of 
active SF/HGF to Met results in auto-phosphorylation of the receptor, which leads to 
full receptor activation and recruitment of signalling adaptor molecules.  
Phosphorylation of two tyrosine residues, Tyr1234 and Tyr1235, within the catalytic 
site results in positive modulation of the enzyme activity, whereas phosphorylation of 
Ser975 in the juxtamembrane segment inhibits the receptor kinase activity (Trusolino 
and Comoglio, 2002). Two further tyrosine residues, Tyr1349 and Tyr1356, together 
with a short-sequence motif located near the C-terminus of the β chain, constitute a 
multi-docking site, which are essential for all receptor activities in vitro and in vivo 
(Ponzetto et al., 1994). Exon 15 of Met encodes the ATP-binding site of Met kinase 
(Borowiak et al., 2004). Like other nucleotide binding proteins, the ATP-binding site 
has a Rothman motif (GXGXXG). When exon 15 was deleted in mice, the function of 
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Met kinase was totally disrupted resulting in embryonic lethal phenotypes (Bladt et 
al., 1995).   
 
 
Figure 2  Schematic structure of Met protein. 
 
A number of signalling molecules have been identified as direct interacting proteins, 
including the Src tyrosine kinase, the PI3 kinase, the adapter molecules Crk/CRKL. 
Shc, Shp, Grb2 and Gab1 as well as the STAT3 transcription factor that further 
activate downstream signalling factors, such as PLCγ, Shp2, Ras, ERK/MAPK 
(Birchmeier et al., 2003; Trusolino and Comoglio, 2002). Most of these signalling 
pathways were identified in studies that examine Met as transforming oncogene. 
In addition to SF/HGF binding, mechanisms are also known, where the activation of 
Met is independent of ligand-binding. For example, the intracellular pathogen 
Lysteria monocytogenes expresses the factor internalin B (lnlB) for cell-to-cell 
transition. InlB binds to Met and activates Met signalling pathways like SF/HGF 
(Cossart, 2001; Shen et al., 2000). In tumour cells, Met kinase activation was 
INTRODUCTION 23 
 
observed after shedding of the ectodomain (Athauda et al., 2006; Merlin et al., 2009; 
Petrelli et al., 2006). Met has been shown to interact with various cell surface 
molecules, which can trans-activate Met kinase pathways. Such transactivation was 
reported to be mediated by other RTKs such as epidermal growth factor (EGF) 
receptor and RET (Fischer et al., 2004; Ishibe et al., 2009; Jo et al., 2000; Merlin et 
al., 2009; Popsueva et al., 2003), the semaphorin receptor Plexin B1 (Giordano et al., 
2002), and CD44 (Matzke et al., 2007). Ron, a same receptor family member with 
high homology, is known to trigger same signalling pathways and to trans-activate 
Met (Follenzi et al., 2000) . 
 
1.2.2. Met-expressing cells 
First, Met was discovered as an oncogene for human osteogenic sarcoma cell line 
(Park et al., 1986) and subsequently found to be expressed on hepatocytes and to 
induce proliferation of these cells (Matsumoto and Nakamura, 1993). Met signalling 
is known to confer mitogenic, morphogenic and motogenic activity to ectodermal 
cells (Sonnenberg et al., 1993; Streit et al., 1995) and muscle progenitors (Dietrich et 
al., 1999; Scaal et al., 1999) during embryogenesis, and neuronal cells (Garzotto et 
al., 2008; Segarra et al., 2006). Met is normally expressed by epithelial cells (Gentile 
et al., 2008)  and plays an important role in wound healing (Chmielowiec et al., 2007; 
Gentile et al., 2008). Met is additionally found on endothelial cells, melanocytes and 
haematopoietic cells. Expression of Met in the haematopoietic compartment is 
limited to progenitor cells and their antigen-presenting progeny including monocytes 
(Beilmann et al., 2000), B cells (van der Voort et al., 1997), and DCs. However, the 
role of Met signalling in immune cells has remained elusive.  
Met has been found to be expressed on various metastatic cancer cells and in a 
number of cancer cell lines. Met pathway was shown to play an important role in the 
development of cancer through: (1) activation of oncogenic signalling pathways, (2) 
induction of angiogenesis, and (3) induction of cell scattering and metastatic 
mechanisms (Christofori, 2006; Comoglio et al., 2008). Some cancer cells might 
even be dependent on sustained Met activity, as shown for cultured cells of gastric 
carcinomas and non-small cell lung carcinomas. Met is considered as a versatile 
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candidate for targeted therapeutic intervention. A variety of Met antagonists, 
inhibitors and blocking antibodies are being currently developed for application in 
Met-targeted anti-tumour therapies (Boccaccio and Comoglio, 2006; Comoglio et al., 
2008). 
 
1.2.3. SF/HGF-expressing cells in the skin 
SF/HGF is a pleiotropic and non-redundant cytokine with a mitogenic, morphogenic 
and, motogenic activity for various cell types. SF/HGF belongs to the plasminogen 
family of proteins and have a high similarity to plasminogen regarding the structural 
organisation and the activation mechanism. Like plasminogen, SF/HGF is expressed 
as a single-chain precursor and converted to a disulphide-linked heterodimer (~90 
kDa) composed of a 60 kDa α-subunit and a 30 kDa β-subunit. The α-subunit 
contains a hairpin loop and four kringle domains, whereas β-subunit is a serine 
protease homology domain lacking proteolytic activity. Upon SF/HGF binding, the 
Met kinase is activated by receptor dimerization and trans-phosphorylation of 
Tyr1234 and Tyr1235 (Trusolino and Comoglio, 2002). During the embryonic 
development, expression of SF/HGF is supposed to be indispensable as shown by 
the embryonic lethal phenotype of  conventional SF/HGF knockouts (Schmidt et al., 
1995; Uehara et al., 1995). 
Major source of SF/HGF was found in cells of mesenchymal origin (Boccaccio and 
Comoglio, 2006). Several studies define dermal fibroblasts as the main source of 
SF/HGF in the skin, stimulating epithelial cells in a paracrine fashion (Brenner et al., 
2005; Ponzetto et al., 2000). Upon skin infection, dermal fibroblasts are actively 
involved in cellular immune responses in connective tissues, secreting a variety of 
pro-inflammatory cytokines (Apte, 1995; Saalbach et al., 2010). Dermal fibroblasts 
either sense microbial pathogens using PRRs for pathogen-associated molecular 
patterns (PAMPs), or are also stimulated by cytokines at inflammatory sites in an 
autocrine and paracrine manner (Miller and Modlin, 2007; Takeuchi and Akira, 2010). 
Stimulation of fibroblasts with pro-inflammatory stimuli such as IL-1α, IL-1β, TNF-α 
(Tamura et al., 1993). IL-6 (Liu et al., 1994),  cyclic AMPs, forskolin, PGE2 
(Matsunaga et al., 1994), phorbol esters (PMA, PDBu) (Gohda et al., 1992a), various 
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toxins (Gohda et al., 1992a; Gohda et al., 2000; Matsunaga et al., 1994), and growth 
factors such as EGF, TGF-α, PDGF, aFGF, bFGF, IGF-I, IGF-II (Gohda et al., 1994) 
results in production of SF/HGF.  Besides fibroblasts, platelets (Nakamura et al., 
1986), smooth muscle cells, neutrophils, and mast cells are also known to produce 
SF/HGF after activation by tissue injury or inflammatory cytokines (Jiang et al., 2005). 
There are also reports that SF/HGF can be produced by keratinocytes upon skin 
injury and inflammation (Mildner et al., 2007; Nayeri et al., 2006) and vascular 
endothelial cells (Jiang et al., 2005). Secreted SF/HGF is proteolytically inactive and 
binds to heparin and extracellular matrix proteins like fibronectin and vitronectin thus 
stimulating proximate cells locally in a paracrine fashion (Hynes, 2009; Kemp et al., 
2006; Rubin et al., 2001). Interestingly, anti-inflammatory factors such as 
glucocorticoids (Gohda et al., 1992a), 1α.25-dihydroxyvitamin D3 (VD3) (Inaba et al., 
1993) and TGF-β (Gohda et al., 1992b), constitutively expressed in the skin (Schmid 
et al., 1993), inhibit SF/HGF production. Once inflammation arises, the suppression 
of SF/HGF production is supposed to be abrogated. 
 
1.2.4. Role of Met in DC function 
In the hematopoietic system, Met expression is limited to HSC and antigen-
presenting cells including DCs. Stimulation with SF/HGF induced the auto-
phosphorylation of Met in DCs demonstrating functional activity of Met signalling. 
Met signalling impacts on the migratory property of LC and DCs as evidenced by the 
observations that activation of Met by ligand enhances adhesion of BMDCs to 
laminin and induces LC emigration from skin, whereas SF/HGF is not a 
chemoattractant for DCs (Kurz et al., 2002). SF/HGF stimulation led to emigration of 
LCs from skin.  Other studies investigated for the potential role of SF/HGF as a 
factor involved in DC differentiation (Ovali et al., 2000; Rutella et al., 2006a) or in 
immune regulation. Studies in specific disease models like  graft-versus-host disease 
or experimental auto-immune encephalomyelitis (EAE) showed evidences for a role 
of Met in immune regulation (Benkhoucha et al., 2010; Kuroiwa et al., 2006; 
Moransard et al., 2010). However, so far findings are highly controversial and studies 
in the same disease model even came to opposite conclusions. For example, 
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Benkhoucha et al. found SF/HGF inhibits EAE by inducing tolerogenic DCs and 
CD25+Foxp3+ regulatory T cells. At the same time, Moransard et al. described an 
opposite role of Met in the same disease model (Moransard et al., 2010). In line with 
the findings of Moransard et al, Beilmann et al. found a pro-inflammatory role of 
SF/HGF based on SF/HGF-induced invasiveness of monocytes (Beilmann et al., 
2000). Supporting the immunoregulatory function of SF/HGF, Okunishi et al. found 
an immunosuppressive effect of SF/HGF on DCs in an experimental model of airway 
inflammation (Okunishi et al., 2005). In contrast, Okada et al. found an elevated 
expression of Met mRNA in DCs in the thymus of the mouse strains that 
spontaneously develop auto-immune diseases (NZB, NZB x NZW F1, BXSB-Yaa, 
MRL/lpr, NOD) and suggested a role of Met in the loss of immune tolerance 
induction, which may be maintained by thymic DCs in other mouse strains (Okada et 
al., 2007).  
 
 
1.3. Aim of the study 
Beyond its well-recognized fundamental roles in development and tumourigenesis 
the function of Met kinase in the immune system has been not yet well understood. 
Only a few studies have evaluated the role of Met in DCs and DC progenitors. 
Results from studies focussing on a potential role in modulating immune responses 
are highly controversial (Kurz et al., 2002; Okunishi et al., 2005). In the initial studies 
in experimental mouse system, it was found that ligand-activated Met regulates DC 
adhesion to extracellular matrix components but leaves antigen presenting function 
in vitro unaffected. SF/HGF is not a chemoattractant factor for DCs, however ear 
sheet explants experiments revealed that activation of Met induces emigration of 
LCs from skin (Kurz et al., 2002), thus indicating for an important role of Met for DC 
migration. 
The objective of this study is to investigate the role of SF/HGF and Met for DC 
mobilization and migration in more detail. Studying the function of Met signalling in 
vivo has been hampered by the fact that classical Met and SF/HGF knockouts are 
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embryonically lethal (Bladt et al., 1995; Schmidt et al., 1995; Uehara et al., 1995). C. 
Birchmeier et al. developed a conditional Met knockout mouse model (Borowiak et 
al., 2004) that was used here to explore Met function for DC mobilization and 
migration in vivo.   
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Mouse strains 
  Strain name Source 
(BL6) WT C57BL/6 In-house breeding 
CCL17e/e C57BL/6-Tg(CCL17-EGFP) IMCAR, RWTH  
(Prof. C. Weber) 
CD45.1 B6.SJL-Ptprca Pepcb/BoyJ Med Clinics III, RWTH  
(Dr. F. Tacke) 
GFP21-loxP STOCK Tg(CAG-Bgeo/GFP)21Lbe/J In-house breeding 
Met -/? C57BL/6-(c-met) In-house breeding 
Met flox/? C57BL/6-Tg(c-met-P) In-house breeding 
Mx-Cre B6.Cg-Tg(Mx1-Cre)1Cgn/J In-house breeding 
OTII C57BL/6-Tg(TcraTcrb)425Cbn/J In-house breeding 
SV129 WT 129/SvJ In-house breeding 
 
2.1.2. Antibodies 
2.1.2.1. FACS antibodies and other detection reagents 
Target protein Clone Company Label 
CCR7 Recombinant 
CCL19  
S. Krautwald, Uni of 
Kiel 
human FC-conjugated 
CD8α 53-6.7 eBioscience Pacific Blue-conjugated 
CD11b M1/70 BD Biosciences AlexaFluor488-
conjugated 
CD11b M1/70 Invitrogen FITC-conjugated 
CD11c N418 eBioscience PE-/APC-conjugated 
CD40 1C10 eBioscience APC-conjugated 
CD45.1 A20 BD Biosciences FITC-conjugated 
CD80 1G10 BD Biosciences Biotinylated 
CD83 Michel-17 eBioscience Purified 
MATERIALS AND METHODS 29 
 
CD86 B7-2 eBioscience FITC-conjugated 
CD103 M290 BD Biosciences FITC-/PE-conjugated 
CD205 NLDC-145 Miltenyi Biotec Biotinylated 
CD207/Langerin 929F3 Dendritics AlexaFluor488-
conjugated 
CD209 5H10 BD Biosciences Biotinylated 
Met eBioclone7 eBioscience PE-conjugated 
MHC II (I-A/I-E) 2G9 BD Biosciences FITC-conjugated 
 
2nd detection reagents Company Label 
Streptavidin Invitrogen FITC-/APC-conjugated 
Streptavidin Jackson Laboratories PE-conjugated 
Anti-rat IgG Invitrogen AlexaFluor488-conjugated 
Anti-rat F(ab’)2 Caltag PE-conjugated 
Anti-human IgG Sigma FITC-conjugated 
 
2.1.2.2. Westernblot antibodies 
Target protein Clone Source Company Dilution 
p44/42 MAPK (Erk1/2) 2137F5 Rabbit Cell signaling 1:1000 
phospho-p44/42 MAPK 
(pErk1/2) 
D13.14.4E Rabbit Cell singaling 1:1000 
β-Actin AC-74 Mouse Sigma-Aldrich 1:7500 
Cre polyclonal Rabbit Merk 1:10000 
 
Secondary antibodies Source Company Dilution 
HRP 2nd antibody anti-rabbit IgG Donkey GE healthcare 1:5000 
HRP 2nd antibody anti-mouse IgG Sheep GE healthcare 1:5000 
 
2.1.2.3. Immunofluorescence antibodies 
Target protein Clone  Source Label Company Dilution 
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Met eBioclone7 Rat PE-conjugated eBioscience 1:250 
Met Polyclonal Rabbit Purified Santa Cruz 1:200 
CD45.1 A20 Rat FITC-
conjugated 
BD 
Biosciences 
1:500 
MHCII (I-A/I-E) M5/114.15.2 Rat Purified BD 
Biosciences 
1:500 
MHCII (I-A/I-E) 2G10 Rat FITC-
conjugated 
BD 
Biosciences 
1:1000 
CD207/Langerin 929F3 Rat AlexaFluor488-
conjugated 
Dendritics 1:150 
 
Secondary antibodies Source Label Company Dilution 
Anti-rabbit IgG (whole 
molecule) 
Goat TRITC-conjugated Sigma 1:250 
Anti-rat IgG (whole 
molecule) 
Rabbit TRITC-conjugated  Sigma 1:200 
 
2.1.3. Buffers and reagents 
2.1.3.1. Media 
• RPMI 1640 medium purchased from Invitrogen 
• DC medium: RPMI 1640 medium containing 10% heat-inactivated (heated for 30 
min at 56°C) FCS, 100 U/ml penicillin and streptomycin sulphate (all purchased 
from Invitrogen) and 50 µM β-mercaptoethanol (Sigma) 
 
2.1.3.2. Growth factors/Cytokines 
• Murine GM-CSF produced in E. coli transformed with the plasmid pETH2aHIS-
mGM-CSF (S. M. Kurz, PhD thesis, 2000) or purchased from Pharmedartis GmbH, 
Aachen 
• SF/HGF: Recombinant Mouse HGF from eBioscience 
• Murine SCF recombinantly produced in CHO cells, cell supernatant was tested for 
SCF activity and applied without further purification 
• Recombinant Flt3-ligand from Peprotech 
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• Recombinant human long-range IGF-1 and dexamethasone from Sigma-Aldrich 
• Recombinant IL-6/soluble IL-6R fusion protein provided by S. Rose-John, Kiel 
• CCL19/ELC, CXCL12/SDF-1 from Peprotech 
• Vitamin D3, 1α25-dihydroxyvitamin D3 from Calbiochem 
• Recombinant human TGF-β from Peprotech or R&D Systems 
 
2.1.3.3. Chemicals and other reagents 
If not stated otherwise, all chemicals were purchased from Sigma-Aldrich, Merck or 
Fluka in analytical grade quality 
• Polyinosinic-polycytidylic acid sodium salt, γ-irradiated from Sigma-Aldrich 
• Polyinosinic-polycytidylic acid sodium salt, double-stranded from Calbiochem 
• Lipopolysaccharides from Escherichia coli 055:B5 from Sigma-Aldrich,  
• Collagenase from Clostridium hystolyticum, Type V from Sigma-Aldrich,  
• Saponin from quillaja bark from Sigma-Aldrich 
• Fluorescein 5(6)-isothiocyanate, approx. 90% HPLC, Tetramethylrhodamine 
isothiocyanate, mixed isomers, 1-Fluoro-2,4-dinitrobenzene from Sigma-Aldrich 
• Protease inhibitor cocktail Complete, EDTA-free from Roche 
• [3H] thymidine form GE Healthcare 
• Met Kinase inhibitor SU11274 from Calbiochem 
• OVA peptide I (257-264, SIINFEKL), OVA peptide II (323-339, 
ISQAVHAAHAEINEAGR) from AnaSpec Inc, San Jose, USA 
• BD MatrigelTM Basement Membrane Matrix, growth factor-reduced from BD 
Bioscience 
• Anti-CD4, anti-CD11c microbeads from Miltenyi Biotec 
• DAPI from Vector Laboratories 
• Mounting medium: ProLong Gold antifade reagent from Invitrogen 
• DAKO pen from Dako 
• Reverse transcriptase: Revert-Aid RT, Recombinant Taq DNA Polymerase, 
RiboLock Ribonuclease Inhibitor for RNase inhibition from Fermentas 
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• DNA ladder: Gene Ruler 1kb ladder, Gene Ruler 100bp ladder plus from 
Fermentas 
• Protein ladder: Page Ruler Prestained Protein Ladder from Fermentas 
 
2.1.3.4. Buffers and other solutions 
Protein chemistry 
• Lyisis buffer: 20 mM Tris, 150 mM NaCl, 10% (v/v) glycerol, 1% NP-40, 0.5 % (v/v) 
Triton X-100, 1 mM Na3VO4, 50 mM NaF, 1x protease inhibitor cocktail (Complete; 
Roche) pH 7.4; Na3VO4, NaF, and protease inhibitor cocktail were given freshly to 
lysates 
• Bradford Assay solution for protein quantification from Biorad Laboratories 
• 2x Laemmli sample buffer: 60 mM Tris/HCl, 20% (v/v) glycerol, 4% SDS, 2% (v/v) 
β-mercaptoethanol, 0.001% Bromphenol Blue,  pH 6.8 
• 5x Laemmli sample buffer: 60 mM Tris/HCl, 50% (v/v) glycerol, 10% SDS, 10% 
(v/v) β-mercaptoethanol, 1.5% Bromphenol Blue,  pH 6.8 
• 1x TBS: 20 mM Tris HCl, 137 mM NaCl, pH 7.6 (also prepared as 10x stock) 
• 1xTBST:  20 mM Tris HCl, 137 mM NaCl, 0.5% (v/v) Tween-20, pH 7.6 
• Ponceau solution: 0.5% Ponceau S, 1% (v/v) acetic acid 
• Coomassie staining solution: 0.1% Coomassie Brilliant Blue, 40% (v/v) methanol, 
10% (v/v) acetic acid 
• Destaining solution: 40% (v/v) methanol, 10% (v/v) acetic acid 
• SDS running buffer: 0.25 M Tris, 1.92 M glycine, 1% SDS 
• Transfer buffer: 48 mM Tris, 39 mM glycine, 20% (v/v) Methanol 
• 2x zymographic sample buffer: 125 mM Tris-HCl, 20% (v/v) glycerol, 4% SDS, 
0.005% bromphenol blue 
• 1x Zymographic renaturing buffer: 2.5 % (v/v) Triton X-100 (prepared as 10x stock) 
• 1x Zymographic developing buffer: 50 mM Tris, 0.2 M NaCl, 5 mM CaCl2 
 
Molecular Biology  
• PBS, diluted from 10x stock of Dulbecco’s PBS without Ca2+ & Mg2+ from PAA 
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• Mouse tail lysis solution: 50 mM NaOH 
• Mouse tail lysis buffer: 1 Tris/HCl, 10 mM EDTA, pH 8 
• 1x TBE: 8.9 mM Tris, 8.9 mM Boric acid, 2 mM EDTA (prepared as 10x stock) 
 
Cell Biology 
• Ficoll “LSM 1077 Lymphocyte” from PAA Laboratories for density gradient 
centrifugation 
• 1x Red blood cell lysis buffer: 150 mM NH4Cl, 10 mM KHCO3, 10 mM EDTA, pH 
7.4 (prepared as 10x stock) 
• FACS buffer: 1% BSA in PBS 
• MACS buffer: 0.5% BSA, 2 mM EDTA in PBS, sterile-filtered 
• 4% PFA: dissolve 4% (w/v) paraformaldehyde in cytoskeleton buffer containing 10 
mM PIPES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl2, 5 mM glucose, pH 7.0 at 
60 °C, stored at -20°C 
• Dynabeads, 15 µm diameter  from Dynal Polymers 
 
2.1.4. PCR primer 
2.1.4.1. Semi-quantitative RT-PCR 
Gene Primer sequence Annealing 
temp. 
Cycle 
no. 
Amplicon 
size 
Gapdh FW: 5’-ggggTgAggCCggTgCTgAgTAT-3’  
60°C 
 
20 
 
459 bp RV: 5’-CATTgggggTAggAACACggAAgg-3’ 
Met FW: 5’-CATTCTggTgCTgcTgTTgTCC-3’  
57°C 
 
25 
 
314 bp RV: 5’-TgTCTTTCCAAACCCCTCCTg-3’ 
Met 
exon 15 
FW: 5’-CTgTTCACATTgACCTCAgTgCTC-3’  
56°C 
 
25 
 
295 bp RV: 5’-CTCAggCAgATTCCCAAgAgTg-3’ 
MMP2 FW: 5’-CCCCTATCTACACCTACACCAAGAAC-3’  
60°C 
 
30 
 
576 bp RV: 5’-CATTCCAggAgTCTgCgATgAgC-3’ 
MMP9 FW: 5’-AgTTTggTgTCgCggAgCAC-3’  
57°C 
 
25 
 
754 bp RV: 5’-TACATgAgCgCTTCCggCAC-3’ 
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Relb FW: 5’-ggTgACggCgTgCCTggTgTg-3’  
62°C 
 
25 
 
407 bp RV: 5’-ACggCCCgCTCTCCTTgTTgATTC-3’ 
SF/Hgf FW: 5’-CATTCAAggCCAAggAgAAg-3’  
55°C 
 
35 
 
208 bp RV: 5’-AACTCggATgTTTgggTCAg-3’ 
Tubulin-
β5 
FW: 5’-gATCggTgCTAAgTCCTgggA-3’  
60°C 
 
18 
 
103 bp RV: 5’-CACAgAgATTCggTCCAgCTg-3’ 
Tnfa FW: 5’-ggCAggTCTACTTTggAgTCATTgC-3’  
60°C 
 
25 
 
307 bp RV: 5’-ACATTCgAggCTCCAgTgAATTCgg-3’ 
 
2.1.4.2. Genotyping 
Mx-Cre FW: 5’-TTCACggTTTCAATTCTCCTCTgg-3’  
63°C 
 
35 
 
440 bp RV: 5’-CACCggCATCAACgTTTTCTTTC-3’ 
fl-Met FW: 5’-AgCCTAgTggAAATCTCTgTAAg-3’  
62°C 
 
32 
 
330 bp/ 
372bp RV: 5’-CCAAgTgTCTgACggCTgTg-3’ 
KO-Met FW: 5’-CTTgCgTgCAATCCATCTTgTTCAATg -3’  
70°C 
 
40 
 
310 bp RV: 5’-CACTgAgCCCAgAAgAgCTAgTgg-3’ 
WT-Met FW: 5’-CTTTTTCAATAgggCATTTTggCTgTg-3’  
70°C 
 
40 
 
520 bp RV: 5’-gTACACTggCTTgTACAATgTACAgTTg-3’ 
 
2.1.5. Kits 
• NucleoSpin RNA II Kit from Macherey-Nagel, Düren for total RNA extraction 
• RNeasy Mini Kit from Qiagen, Hilden for total RNA extraction 
• Nucleospin extract II from Macherey-Nagel Düren for DNA extraction  
• High Capacity cDNA RT Kit from Applied Biosystems for cDNA synthesis 
• Cytometric Bead Array (CBA) Kit from BD Biosciences 
 
2.1.6. Consumable materials 
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• Photometer-plate: Costar UV Plate, 96 well, No Lid with UV Transparent Flat 
Bottom, Nonsterile, Acrylic 
• 6.5mm Transwell® with 5.0µm Pore Polycarbonate Membrane Insert Sterile form 
Corning Costar 
• Westernblot membrane: Nitrocellulose membrane 0.45 Micron, 30 cm x 3.5 m roll 
from Thermo Scientific 
• X-Ray film for Westernblot: CX-XPosure™ 18x24cm Clear Blue x-Ray Film 
• Printed FilterMat A, Glass fibre filter size 90 x 120 mm from PerkinElmer 
• MultiLex™ A Melt-on Scintillator Sheets size 73 x 109 mm from PerkinElmer 
• Cell Strainer, 70 µm, 40 µm from BD Falcon™ 
• Sterile pipette tips: Molecular BioProducts ART® Aerosol Resistant Tips 10, 20, 
200, 1000   
• MACS Separation Columns 25MS from Miltenyi Biotec 
• FACS tubes from Sarstedt 
• Other cell culture dishes, flasks, disposable pipettes, reaction tubes and centrifuge 
tubes were purchased from Eppendorf, Brand, Nunc, Greiner bio-one, TPP or BD 
Falcon™.  
 
2.1.7. Apparatus and instruments 
• Centrifuges: Sigma 2K15, Eppendorf Centrifuge 5424, Heraeus Multifuge 3 L-R, 
Heraeus Multifuge 3 L 
• Thermixer: Eppendorf Thermomixer compact 
• Cell counter + flow cytometer: Schärfe system/INNOVATIS Casy cell counter + 
analyzer Model TTC 
• Flow cytometer: BD FACS Calibur, BD FACS Canto II 
• Incubator: Heraeus Heracell 240 
• Scales: Sartorius CP225D, Kern 572-45 
• PCR cycler:  Eppendorf Mastercycler® ep, MJ Research, Inc., DNA engine  
• Microscopes: Zeiss Axiovert200, Zeiss Axioplan2, Zeiss Stemi SV6 
• CCD camera: Photometrix cascade 512B 
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• Gel document system: Biorad Gel doc X 
• Scintillator: Wallac 1450 MicroBeta TriLux 
• Photometer: Molecular Devices SPECTRAMax PLUS 384 
• UV lamp: Kojair ‘UV Lampe mit Magnetsockel 30W 503130’ with Sylvania UVC-
bulb G30T8 30W G13 895mm T8 
• Computer: Apple Mac mini, Apple Power Mac G5, Samsung Q70 notebook 
 
2.1.8. Softwares 
IPlab, Adobe Photoshop CS, Adobe Reader, Microsoft Office 2008 for Mac, FlowJo 
8.6.2 for Mac, BD CellQuest Pro, Macromedia FreeHand Mx, Endnote X2 etc. 
 
 
2.2. Methods 
2.2.1. Mice 
C57BL/6, CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), and OT-II mice (C57BL/6-
Tg(TcraTcrb)425Cbn/J) were bred at University Hospital Aachen. Mice heterozygote 
for the Met knockout allele (Met+/-) were crossed to transgenic mice expressing Cre 
under the control of the Type I IFN-inducible Mx promoter (Mx-Cre x Met+/-) 
(Borowiak et al., 2004; Kuhn et al., 1995; Schneider et al., 2003). Mx-Cre x Met+/- 
mice were crossed to Metflox/flox mice to generate Mx-Cre x Metflox/- and Mx-Cre x 
Metflox/+ offspring. 
To mutate the floxed Met allele, 5-7 week old Mx-Cre x Metflox/- or Mx-Cre x Metflox/+ 
mice were injected on subsequent 5 days i.p. each with 300 µg of 
polyinosinic/polycytidylic acid (pI:pC; 1:1; w/w; Merck) in PBS resulting in conditional 
Met-deficient MetD/- mice (referred to as Met KO)  or wild-type control MetD/+ mice 
(Met WT).  
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All mice were maintained under specific pathogen free conditions in the central 
animal facility of the University Hospital Aachen. All animal experiments were 
approved by local authorities (Bezirksregierung Köln) in compliance with the German 
animal protection law. 
 
2.2.2. Transplantation of BM cells for generation and analysis of LC 
chimeric mice  
BM transplantations were performed essentially as previously described 
(Hieronymus et al., 2005). Briefly, CD45.1+ recipient mice were lethally irradiated 
with two doses of 5.5 Gy each at a 4-h interval, and a total of 2x106 BM cells from 
CD45.2+ Met WT or Met KO mice were injected intravenously. Donor chimerism was 
evaluated by flow cytometry analysis of BM, blood, and lymphatic organs in control 
mice and was ≥95% for donor cells seven weeks after transplantation. To achieve 
LC chimerism in skin epidermis 7 weeks after BM transplantation mice were exposed 
to UV light (30 min at a distance of 30 cm, wavelength = 254 nm, total dose 16.8 kJ) 
to induce ear skin inflammation as described (Merad et al., 2002). The presence of 
donor- and host-derived LCs in the epidermis was investigated 9 weeks after UV 
irradiation by immunofluorescence analysis of the epidermal sheets. BM of recipient 
mice was isolated at the same time and genotyped for wild-type, knockout, and 
floxed Met alleles to exclude incomplete Met deletion in donor BM cells from Met KO 
mice. 
 
2.2.3. MACS purification of DCs 
CD11c+ DCs were isolated from the freshly isolated spleen or collagenase-digested 
epidermal tissue using MACS purification system (Miltenyi Biotec). MACS was 
performed according to the manufacturer’s protocol. Briefly, freshly isolated spleen 
cells or collagenase-digested epidermal tissue were washed with MACS buffer (0.5% 
BSA, 2 mM EDTA in PBS), mixed with magnetic anti-CD11c-microbeads and 
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incubated for 15 min at 4°C. The magnetically labelled cells were retained in a 
separation column placed in a magnetic field and recovered from the elute. 
 
2.2.4. Flow cytometry 
Flow cytometry analysis was carried out as previously described (Kurz et al., 2002). 
Briefly, < 106 cells were stained with antibodies for 20 min after a wash in FACS 
tubes with 2 ml FACS buffer (1% BSA in PBS). Purified antibodies are further 
labelled with fluorochrom-conjugated species-matched secondary antibodies. 
Biotinylated antibodies were detected by FITC-or PE-conjugated streptavidin 
(Invitrogen).   
 For detection of Langerin, cells were first fixed with 4% PFA and permeabilized with 
1% saponin in PBS (Sigma-Aldrich) at 4°C for 15 min each. Multiparameter flow 
cytometric analyses of stained cell suspensions was performed on a FACSCalibur or 
FACSCantoII (BD Biosciences) and analysed with FlowJo software (Tree Star). 
 
2.2.5. DC/LC analyses in skin 
Ears from mice were split into dorsal and ventral halves and incubated in PBS/0.02 
M EDTA (Sigma-Aldrich) for 90 min at 37°C to allow separation of epidermis from the 
dermis. Dermal and epidermal cell suspensions were obtained by digestion with type 
V collagenase (1mg/ml, Sigma-Aldrich) at 37°C for 30 min. Cell suspensions were 
passed through a 21-gauge syringe needle and a cell strainer and the presence of 
LCs, and dermal DCs in skin epidermis and/or dermis was assessed by flow 
cytometry. 
 
2.2.6. In vitro DC cultures 
2.2.6.1. Two-step generation of BMDC with GM-CSF (two-step GMDC)  
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DCs were generated in vitro from mouse BM using a two-step amplification and 
differentiation protocol as previously described (Hieronymus et al., 2005). Briefly, BM 
cells were flushed out from femur and tibia and cultured in RPMI 1640 medium 
supplemented with 10% FCS (Invitrogen), 100 ng/ml recombinant murine SCF, 25 
ng/ml Flt3-ligand (Peprotech), 40 ng/ml recombinant human long-range IGF-1 
(Sigma-Aldrich), 5 ng/ml recombinant IL-6/soluble IL-6R fusion protein (Fischer et al., 
1997); kindly provided by S. Rose-John), 20 U/ml recombinant murine GM-CSF, and 
10-6 M dexamethasone (Sigma-Aldrich). After 5 to 9 days in culture differentiation of 
amplified cells into DC was induced in culture medium supplemented with 200 U/ml 
recombinant murine GM-CSF. Immature DCs obtained after 10 to 12 days under 
differentiation conditions were used for experiments and stimulated with 40 ng/ml 
with SF (eBiosciences) or left untreated. In some experiments 1 µg/ml LPS was 
added 24 h prior to treatment with SF to induce DC maturation. 
 
2.2.6.2. One-step generation of BMDC with GM-CSF (one-step GMDC) 
DCs were generated in vitro from mouse BM using a one-step protocol described by 
Lutz et al (Lutz et al., 1999). Briefly, BM cells were flushed out from femur and tibia, 
and 2 x 106 BM cells were plated in 10 ml RMPI 1640 medium supplemented with 10% 
FCS (Invitrogen) and 20 U/ml recombinant murine GM-CSF. After 3 days, 10 ml 
RPMI 1640 medium supplemented with 10% FCS and 20 U/ml recombinant murine 
GM-CSF were further added to the cells. A partial medium change (~50%) was 
performed at day 6 and day 8 of culture. At day 9 or 10, immature DCs were 
harvested for experiments, stimulated with 40 ng/ml with SF/HGF (eBiosciences) or 
left untreated. In some experiments 1 µg/ml LPS was added 24 h prior to treatment 
with SF/HGF to induce DC maturation. 
 
2.2.6.3. 1α,25-dihydroxvitamin D3 (VD3)-induced generation of BM-derived 
tolerogenic DC 
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One-step or two-step GMDCs were generated according to protocol described in 
2.2.6.1 and 2.2.6.2 and pre-treated for 24 h with VD3 at 10-6 M before induction of 
maturation. 
 
2.2.6.4. TGF-β-induced generation of BM-derived LC-like cells and tolerogenic DC 
One-step GMDCs were generated according to protocol described in 2.2.6.1 in the 
presence of 5 ng/ml huTGF-β (Peprotech) and with DC medium supplemented with 
semi-inactivated (heated for 15 min at 42°C) FCS. 
 
2.2.6.5. Two-step generation of BMDC with Flt3-ligand (FLDC) 
DCs were generated in vitro from mouse BM using a protocol established by Piritta 
Felker (Felker et al., 2010), which was modified from Hieronymus’ two-step protocol 
(Hieronymus et al., 2005) and previously described protocols (Brawand et al., 2002; 
Gilliet et al., 2002; Naik et al., 2005). Briefly, BM cells were flushed out from femur 
and tibia and cultured in RPMI 1640 medium supplemented with 10% FCS 
(Invitrogen), 100 ng/ml recombinant murine SCF, 25 ng/ml Flt3-ligand (Peprotech), 
40 ng/ml recombinant human long-range IGF-1 (Sigma-Aldrich), and 5 ng/ml 
recombinant IL-6/soluble IL-6R fusion protein (Fischer et al., 1997); kindly provided 
by S. Rose-John). After 5 to 7 days in culture differentiation of amplified cells into DC 
was induced in culture medium supplemented with 50 ng/ml Flt3-ligand. The culture 
medium was partially (~80%) replaced at day 5, 8. Immature DCs obtained after 10 
days under differentiation conditions were used for experiments. 
 
2.2.7. Ex vivo migration assay 
Ex vivo migration assay was performed as previously described (Kurz et al., 2002; 
Larsen et al., 1990). Ears from mice were split into dorsal and ventral halves and 
incubated split-side down for 3 days at 37°C in RPMI 1640 medium containing 10% 
FCS and GM-CSF (200 U/ml), plus SF/HGF (40 ng/ml), TNF-α (100 ng/ml), LPS (1 
µg/ml) or no factor. Ear sheets were removed and epidermis was isolated, acetone-
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fixed and subjected to immunofluorescence microscopy. Cells that have migrated 
into the culture medium were harvested and stained with anti-CD11c-APC, anti-
langerin-Alexa488, and anti-Met-PE and analysed by flow cytometry. To allow 
normalization for numbers of migrated DCs 1 × 104 Dynabeads (15-µm diameter; 
Dynal Polymers) were added to the culture medium and cells and beads were 
recovered before staining of cells. By gating on beads, the ratio of beads to CD11c+ 
langerin+ DC was determined and allowed a precise calculation of the number of 
emigrated LCs. 
 
2.2.8. Immunofluorescence microscopy 
Cryosections of LNs (5-µm thickness) and epidermal sheets were fixed in 100% ice-
cold acetone for 20 min, rinsed in PBS and blocked with PBS/3% BSA (Sigma-
Aldrich) for 30 min at room temperature before staining. Fluorochrome-conjugated 
primary antibodies for detection of Met, langerin and MHC class II were diluted in 
blocking buffer and samples incubated overnight at 4°C. For some experiments an 
unconjugated rat anti-mouse I-A/I-E antibody (clone M5/114.15.2; BD Biosciences) 
and a tetramethylrhodamine-isothiocyanate (TRITC)-conjugated rabbit anti-rat IgG 
(Sigma-Aldrich) as a secondary reagent was used for detection of MHC class II. 
After incubation with antibodies samples were washed three times with PBS and 
counterstained with DAPI (Vector Laboratories) before being mounted in ProLong 
Gold mounting media (Molecular Probes). Images were acquired using an Axiovert 
200 fluorescence microscope (Zeiss) and a digital CCD camera (Roper Scientific) 
operated with IPlab software. Image processing was done with Adobe Photoshop 
software. 
 
2.2.9. Antigen-specific T cell activation 
CD4+ T cells from OT-II mice expressing a transgenic TCR that recognizes OVA323-
339 peptide on I-Ab were prepared by immunomagnetic bead purification of 
splenocytes using MACS anti-CD4 microbeads (Miltenyi Biotec) according to 
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manufacturer’s instructions. Immature and LPS-matured DC from Met WT and Met 
KO mice stimulated with 40 ng/ml SF/HGF for 16 h or left untreated were pulsed with 
0.1 mM OVA323-339 peptide (ISQAVHAAHAEINEAGR) for 30 min and then co-
cultured at various rates with isolated OT-II CD4+ T cells in 96-well microtiter plates. 
At day 4 of co-culture, 0.75 µCi/well [3H]thymidine (GE Healthcare) was added per 
well, cells were harvested 5 h later, and [3H]thymidine incorporation was measured 
with a scintillation counter (MicroBeta Trilux, Wallac). Experiments were done with 
triplicate samples. 
 
2.2.10. Skin DC migration assay 
Skin DC migration kinetics towards the draining LN was analysed 24 h to 72 h after 
FITC/TRITC painting. 100 µl of 1 % TRITC, 100 µl of 0.5% FITC or 50 µl of 0.2% 
FITC solubilized in acetone/dibutyl phthalate solution (1:1, vol/vol) were a painted on 
shaved abdomen of mice. Axillary and inguinal LNs and non-draining mesenteric 
LNs as control were isolated 24 h after TRITC painting. Brachial and inguinal LNs 
and non-draining mesenteric LNs were isolated 24 h, 48 h and 72 h after FITC 
painting. The isolated LNs were dissociated to single cell suspensions, and analysed 
for migrated LC and dermal DC populations by flow cytometry. 
 
2.2.11. Contact hypersensitivity responses 
FITC and 2,4-dinitrofluorobenzene (DNFB, Sigma-Aldrich) were used as allergens to 
induce contact hypersensitivity responses. Mice were sensitized by applying 400 µl 
of 0.5% FITC solubilized in acetone/dibutyl phthalate solution (1:1, vol/vol) or 20 µl of 
0.5% DNFB in acetone/olive oil (4:1, vol/vol) on their shaved abdomen. Immunization 
with DNFB was repeated after 24 h. In some experiments the Met-specific kinase 
inhibitor SU11274 (Merck) dissolved in DMSO (200 µM, f. c.) was applied 30 min 
before immunization with DNFB. Control animals received DMSO alone before 
immunization. Basal ear thickness was measured five days after initial immunization 
with a digital micrometer gauge (Hogetex) before applying 10 µl of 1% FITC solution 
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or 0.2% DNFB solution to both ventral and dorsal skin surfaces of the right ears to 
elicit a CHS reaction. As control, left ears were treated accordingly with the same 
volume of solvents only. CHS responses were determined by gauging the ear 
swelling of both left and right ears 24 h later and increase in ear thickness is 
displayed. 
 
2.2.12. Transwell migration assay 
Transwell migration assay was performed essentially as described previously 
(Hieronymus et al., 2005) with minor modifications. Transwell inserts (5-µm pore 
size, Costar) were coated with BD MatrigelTM Basement Membrane Matrix diluted 1:3 
with serum-free DC medium at 37°C overnight or left uncoated. Before use, the 
membranes were equilibrated with serum-free DC medium for 1 – 2 hours. To 
analyse migration of DC towards a chemokine gradient, 2 × 105 cells, which had 
been activated with LPS overnight and treated with SF/HGF for 30 min, were seeded 
in the upper compartment and CCL19/ELC or CXCL12/SDF-1 chemokines (100 
ng/ml, Peprotech) were added to the lower compartment. 
Transmigration of DCs through uncoated transwell inserts and through Matrigel 
matrix was analysed after 90 min and after 5 h, respectively. Numbers of 
transmigrated cells were normalized as done in ex vivo migration assays by adding 1 
x 104 Dynabeads per sample to the lower chamber before cells were analysed. Cells 
and beads were recovered and counted by flow cytometry. 
 
2.2.13. Immunoblotting 
Western blot analysis was carried out essentially as described before (Hieronymus 
et al., 2000). Briefly, cells were lysed after the indicated time in lysis buffer containing 
20 mM Tris, pH 7.4, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP-40, 0.5% (v/v) 
Triton X-100, 1 mM Na3VO4, 50 mM NaF, and protease inhibitor cocktail (Complete; 
Roche) for 1 h at 4°C. Supernatants were clarified by centrifugation for 15 min at 
14,000 x g at 4°C and protein concentrations was determined using Bradford assay 
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(Biorad). 20 µg of total protein lysates from each sample were boiled in Laemmli 
sample buffer for 5 min and resolved by SDS-PAGE in SDS running buffer 
containing 0.25 M Tris, 1.92 M glycine and 1% SDS followed by semi-dry electro-
blotting onto nitrocellulose membrane equilibrated in transfer buffer containing 48 
mM Tris, 39 mM glycine and 20% methanol between Whatmann papers also soaked 
in the transfer buffer. To block unspecific binding membranes were incubated in 
freshly prepared 5% (w/v) nonfat dry milk in TBST for at least 30 min at RT. Total 
and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) were identified 
using rabbit anti-p44/42 MAPK (Erk1/2, clone 137F5, Cell Signaling Technology) or 
rabbit anti-phospho-p44/42 MAPK (pErk1/2, clone D13.14.4E, Cell Signaling 
Technology) antibody in blocking buffer, respectively. After overnight incubation at 
4°C and washing with TBST membranes were reacted with horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody (GE Healthcare) in blocking buffer for 90 
min at RT. Detection was performed using enhanced chemiluminescence 
(SuperSignal®, Thermo Scientific). Detection of β-Actin (anti-β-Actin, clone AC-74, 
Sigma-Aldrich) was used as a loading control. 
 
2.2.14. Transcript analysis by reverse transcription polymerase chain 
reaction 
Total RNA was isolated from cells using the NucleoSpin RNA II Kit (Macherey-Nagel, 
Düren) with on-column DNase digestion or RNeasy Mini Kit (Qiagen, Hilden) 
according to manufacturer’s instructions. mRNA was reverse-transcribed using High 
Capacity cDNA RT Kit (Applied Biosystems) according to manufacturer’s instructions 
or the following approach: 0.5 µg to 1 µg RNA was incubated with 0.2 µg random 
hexamer (Fermentas) at 70°C for 5 min (in 20 µl) and then with 1x reaction buffer 
(provided with Revert-Aid RT, Fermentas), dNTP mix (10 mM each), and 20 U 
RiboLock Ribonuclease Inhibitor at RT for 5 min. After adding 200 U Revert-Aid RT, 
the reaction mix (40 µl total reaction volume) was kept at RT for 10 min for primer 
binding and then at 42°C for 60 min for enzyme activity. The reaction was stopped 
by heating at 70°C for 10 min.    
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50 ng cDNA was used as a template for each PCR reaction using gene-specific 
primers and conditions.  
PCR reaction mix 
2 µl 50 ng cDNA 
2 µl 10x taq Pol buffer (NH4)2SO4 
2 µl MgCl2 
0.5 µl FW primer, 10 mM 
0.5 µl RV primer, 10 mM 
0.5 µl dNTP (10 mM each) 
0.3 µl Recombinant Taq DNA Polymerase (Fermentas) 
+ 12.2 µl H2O, total volume: 20 µl 
 
Standard reaction scheme 
   
 
 
5 µl of each PCR reaction was run on a 1% agarose-gel containing ethidiumbromide 
and visualized using GelDocX gel documentation system (BioRad). 
 
2.2.15. Zymography 
SDS-polyacrylamide gels were poured with 0.1% gelatin additionally to standard 
composition. DC lysates were mixed with 2x sample buffer containing 125 mM Tris-
HCl, 20% glycerol, 4% SDS, 0.005% bromphenol blue for 10 min before being 
subjected to gel electrophoresis. After running, gels were renatured with 2.5% Triton 
X-100 in H2O for 30 min and then incubated with developing buffer (50 mM Tris 
Initiation 94°C 2 min 
Denaturation 96°C 1 min 
Annealing Gene-specific annealing temparture 1 min 
Extension 72°C 1 min 
Final extension 72°C 7 min 
Termination 4°C ∞ 
gene-specific 
cycle number 
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base, 0.2 M NaCl, 5 mM CaCl2) overnight at 37°C after equilibration for 30 min at 
room temperature. Degradation of gelatin by MMPs was made visible by staining of 
the gels with Coomassie Blue R-250. 
 
2.2.16. Cytometric bead assay 
Concentration of cytokines released from DCs into culture supernatant was 
determined by Cytometric bead assay (CBA, BD Biosciences) according to the 
manufactor’s instructions. Briefly, bead populations with distinct fluorescence 
intensities were coated with capture antibodies for each cytokine to be measured 
and mixed together in an assay tube. The capture beads were incubated first with 
recombinant standards or culture supernatants of DCs, optionally stimulated with 
LPS or SF/HGF 16 h prior to the collection, and then incubated with the PE-
conjugated detection antibodies. Beads were washed and analysed with 
FACSCantoII. Cytokine concentration was calculated by FCAP (Soft Flow Inc.) 
software.    
 
2.2.17. Statistics 
Statistical analyses were performed using paired, one-tailed Student's t test. P 
values below 0.05 were considered to be significant.  
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3. RESULTS 
3.1. Met expression on DCs in vivo  
DC homeostasis is differentially regulated in steady state and inflammation (Merad et 
al., 2008; Shortman and Naik, 2007), and thus various DC subpopulations were 
analysed in mice for Met expression in lymphoid and non-lymphoid tissues before 
and after DC activation. Met is known to be constitutively expressed on LCs and has 
impacts on LC biology, which also includes the increase in motile property for 
emigrating from epidermis (Kurz et al., 2002). LCs and skin DCs migrate upon 
activation towards the skin draining LN (Alvarez et al., 2008). Met expression was 
found on all DC subpopulations, albeit at different levels according to location and 
activation status.  
 
 
Figure 3. Immunofluorescence analysis of Met expression on DC in vivo. Epidermal 
skin sheets and inguinal LN cryosections from WT mice after skin irritation on the abdomen 
were stained for Langerin (green) and Met expression (red) and counterstained with DAPI 
for nuclear visualization. Scale bar, 50 µm.  
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First, Met expression was examined on steady-state LCs in the ear epidermis and on 
those that had been migrated into the skin draining LNs after activation. In epidermis, 
steady-state LCs expressed low levels of Met (Figure 3, upper panel). In contrast, 
the majority of Langerin+ cells in the skin draining LN after skin irritation gave strong 
Met signal (Figure 3, lower panel). 
 
 
Figure 4. Immunofluorescence analysis of Met expression on DC upon activation in 
vivo. Epidermal skin sheets and cryosections of inguinal LN (ingLN) were obtained from a 
CCL17-EGFP transgenic mouse after skin irritation on the abdomen, where enhanced GFP 
(EGFP) is expressed under control of the CCL17 promotor. CCL17-EGFP epidermal sheets 
and inguinal LN crysections were stained for MHC class II and Met (red), and counterstained 
with DAPI for nuclear visualization. Scale bars, 50 µm.  
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Further, epidermal skin sheets and cryosections of the ingLN from CCL17-EGFP 
transgenic mouse were analysed by immunofluorescence staining either for Met 
(Figure 4, upper panel) or MHC class II expression (Figure 4, lower panel). CCL17 is 
a DC specific chemokine being expressed in activated DCs. In this transgenic mouse 
model, the CCL17 gene was replaced by EGFP reporter, which is expressed under 
control of the CCL17 promotor. Thus, expression of EGFP indicated activated LCs 
and DCs (Alferink et al., 2003). All CCL17+ cells, also positive for MHC class II, 
expressed Met at high levels (Figure 4). 
Next, Met expression on LCs and DCs in different locations was analysed by flow 
cytometry. The majority of epidermal LCs and dermal DCs residing under steady-
state conditions in skin showed low levels of Met expression (Figure 5 A, upper 
panel), which is in line with results from immunofluorescence staining (Figure 3 and 
Figure 4). The Langerin+ DCs in skin-draining LNs showed a high Met expression 
level (Figure 5 A, lower panel). CD103+ cells showed same Met expression pattern 
as CD103-negative cells (Figure 5 B). In the LN, the DC compartment comprises LN-
resident DC subpopulations and tissue-derived DCs immigrated from peripheral 
tissues. However, in steady state the migratory DCs constitute only a minor 
population of all DCs in LN (Jakubzick et al., 2008a). Therefore, mice were 
stimulated either by skin irritation with the contact sensitizer acetone/dibutyl 
phthalate (Figure 5 C, upper panel) or systemic LPS stimulation (Figure 5 C, lower 
panel) to increase the number of skin-derived migratory DCs under inflammatory 
conditions. Skin-derived migratory DCs were found in skin-draining LNs within 
CD11b+ CD8α- population, but not all of CD11b+ CD8α- DCs are skin-derived DCs. 
CD11b+ CD8α- DC subpopulation also comprises a population of LN-resident 
CD11b+ CD8α- DCs. While steady-state LN-resident DCs were MHC class II-
intermediate, tissue-derived migratory DCs were considered as MHC class II-high 
cells (Ohl et al., 2004; Wilson et al., 2008). It was observed that skin irritation of mice 
resulted in remarkable influx of CD11b+ CD8α- DCs into skin draining LNs 
expressing MHC class II on high levels. Here, the increase in the number of CD11b+ 
CD8α- MHC class II-high DCs was higher than after systemic LPS treatment.  
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Figure 5. Flow cytometry analysis of Met expression on DC in vivo. Epidermal skin 
sheets, dermal skin explants, and inguinal LNs were digested and dissociated into single cell 
suspensions. (A) The cells were stained for Met and Langerin. Blots show results after 
gating on CD11c+ cells. (B) From dermal skin explants, CD103+ Langerin+ dermal DCs 
were obtained. The blot shows results after gating on CD45+ CD11b+ F4/80- CD11c+ cells. 
(C) Mice received either skin irritatant (upper panel) or intravenious LPS injection (lower 
panel)., Inguinal LNs were  analysed two days after treatment. 
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LN-resident CD11b- CD8α+ DCs showed lower levels of Met expression than skin-
derived migratory DCs. Within LN-resident DC subpopulations expressing MHC 
class II on intermediate levels, CD11b- CD8α+ DCs expressed higher levels of Met 
than CD11b+ CD8α- DCs (Figure 5 C).   
Spleens were also examined for Met expression in DC subpopulatios under 
inflammatory conditions. Splenic DCs were first purified by MACS and then analysed 
by flow cytometry. Unlike skin-draining LNs, the spleen does not contain skin-derived 
migratory DCs. Here, it could be shown that Met was also expressed on DCs at 
various levels. The majority of CD11b+ CD8α- DCs are MHC class II-intermediate 
that showed lower levels of Met expression than MHC class II-high CD11b+ CD8α- 
DCs (Figure 6).  
 
 
Figure 6.  Flow cytometry analysis of Met expression on DC in the spleen. WT mice 
received either skin irritatant (upper panel) or intravenious LPS injection (lower panel). The 
spleen was dissociated to single cell suspension two days after treatment. Single cells were 
enriched for CD11c+ cells by MACS and stained for CD11c, MHC class II, Met and DC 
subpopulation markers CD11b and CD8α. 
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Next, plasmacytoid DCs (pDCs) were analysed for Met expression. pDCs were 
identified using the mouse specific surface markers PDCA-1 and siglec-H (SigH). 
Here, the focus was on the pDC population in secondary lymphatic organs like in the 
draining inguinal LN (Figure 7 A) and in the spleen (Figure 7 B). pDCs expressed no 
or only low levels of Met in all analysed organs (Figure 7 A and B). 
 
 
Figure 7. Flow cytometry analysis of Met expression on plasmacytoid DCs in LNs and 
the spleen.  (A) Inguinal LNs were digested and dissociated into single cell suspensions. 
The cells were stained for B220, CD11c, Met, siglec-H (SigH), and PDCA-1 and analysed. 
(B) Splenocytes were flushed out of a fresh spleen and enriched for CD11c+ cells by MACS. 
CD11c-enriched cells were then stained for B220, CD11c, Met, siglec-H (SigH), and PDCA-1, 
and analysed. 
 
LCs and dermal DCs were shown to migrate with different kinetics to draining LNs 
upon activation, with dDCs preceding LCs (Allan et al., 2006; Kissenpfennig et al., 
2005). To study migration kinetics and Met expression of LCs and dermal DCs, DCs 
in the skin were labelled with fluorescent dyes like FITC or TRITC. To this end, 
fluorescent dyes were applied on the shaved abdomen of mice. Skin DCs take up 
these fluorescence dyes as hapten and transport to T cells in the skin draining LNs, 
such as inguinal LN. Skin DCs having taken up the fluorescent dye could be 
detected with immunofluorescence microscopy and by flow cytometry.  
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Figure 8. TRITC painting of CCL17-EGFP transgenic mice. Mice were painted with 100 µl 
of 1% TRITC solved in 1:1 dibutyl phthalate/acetone on shaved abdomen. (A) Inguinal, 
axillary and mesenteric LNs were dissected and dissociated to single cell suspension. Single 
cell suspension was stained for CD11c and analysed by flow cytometry. (B) Cryosections of 
inguinal and mesenteric LN were stained for DAPI for nuclear visualization. EGFP was 
expressed under control of the CCL17 promotor. Arrow heads indicate co-localized cells. 
Scale bars, 50 µm. 
 
First, the migration of skin DCs into LNs was demonstrated by painting of a CCL17-
EGFP transgenic mouse with TRITC solved in 1:1 acetone/dibutyl phthalate, Inguinal, 
axillary and mesenteric LNs were taken out 24 h later and analysed by 
immunofluorescence microscopy. In the skin-draining inguinal LNs, almost all 
CD11c-high cells were found in activated state expressing CCL17 after skin painting. 
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In contrast, in non-draining mesenteric LNs or in draining axillary LN, which was 
situated far from the site of painting, there were not as many cells expressing CCL17 
as in the inguinal LNs (Figure 8 A). In immunofluorescence analysis of the inguinal 
LNs, it could be proven that the activated DCs migrated from skin into inguinal LNs, 
since there were activated DCs expressing CCL17 that were labelled with TRITC. 
The signal of EGFP arisen from the activation of CCL17 gene widely overlapped with 
the TRITC signal (Figure 8 B). 
For flow cytometry analysis, mice were painted with 100 µl of 1 % FITC solution on 
shaved abdomen. After 24 h, 48 h, and 72 h inguinal LNs were dissected. After FITC 
painting, a distinct increase of CD11c+ Met-high cell population was observed 
(Figure 9 A). They were probably skin DCs, which arrived in the draining LNs 
expressing Met. Among FITC-carrying cells, two populations of DCs could be 
distinguished by different levels of Met expression (Figure 9 B). Most of the faster 
migrating DCs that succeeded the LN within 24h showed highest Met expression, 
whereas after 48 h more DCs with intermediate levels of Met were found and 
numbers of FITC-carrying DCs started to decline at later time points (Figure 9 A and 
B).  
These two different populations were further characterized by flow cytometry. Met-
high population was identified as CD205-intermediate CD209+ dermal DC, and Met-
low as CD205-high CD209- LC (Allan et al., 2006; Romani et al., 2006; Soilleux and 
Coleman, 2001) (Figure 9 C). Met expression levels were found lower at all times in 
FITC-carrying LCs than in FITC-carrying dermal DCs concomitant with the different 
migration kinetics of both DC subpopulations (Figure 9 B and C). 
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Figure 9. Migration kinetics of Met+ LCs and dermal DCs. (A and B) Mice were painted 
with 100 µl of 1% FITC solution on shaved abdomen. After 24 h, 48 h, and 72 h inguinal LNs 
were dissected. LNs were dissociated to single cell suspensions. Cells were stained for 
CD11c, MHC class II and Met. (C) LC (CD205-high. CD209-) and dermal DC (CD205-low, 
CD209+) subpopulations of FITC-carrying CD8α-neg/low LN DCs were analysed for Met 
expression. 
 
Taken together, these data show that Met expression on peripheral skin DCs is up-
regulated upon activation suggesting a functional role of Met for DC migration 
towards draining LNs. 
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3.2. Establishing of a conditional Met-deficient mouse model 
3.2.1. Breeding strategy for conditional Met-deficient mice 
Mice lacking expression of Met or its ligand SF/HGF are embryonically lethal (Bladt 
et al., 1995; Schmidt et al., 1995; Uehara et al., 1995). To address the role of Met in 
DC under steady state and inflammatory conditions in vivo, a conditional Met 
knockout (KO) mouse model was employed (Borowiak et al., 2004). In this mouse 
model, exon 15 of Met was flanked by loxP sites, which can be excised by Cre 
recombinase (Figure 10). In this study, Cre recombinase under control of the Mx 
promotor was used. The Interferon (IFN)-inducible gene Mx is known to be required 
for cellular resistance to influenza virus replication. The Cre-based recombination 
using a tissue-specific promotor is not equally efficient in all tissues of the mouse, 
but the activation of Mx-cre by injection of pI:pC has been described to be highly 
effective (~100%) for haematopoietic cells and in BM (Kuhn et al., 1995; Schneider 
et al., 2003). pI:pC is a synthetic analogue to double-stranded RNA and induces IFN 
expression via Toll-like Receptor (TLR) 3 signalling. 
 
 
Figure 10. Schematic representation of the targeting strategy used to generate the 
Metflox allele. Exon 15 of Met (indicated in red) encodes the ATP-binding site of the Met 
kinase. Yellow boxes indicate exons 14 and 16; loxP sites are shown by arrowheads. NEO, 
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neomycin resistance gene; BHI, BamHI, endonuclease cleavage site. Adapted from  
(Borowiak et al., 2004). 
 
The Mx-cre allele was first crossed into classical Met KO mice, where all living 
offsprings are heterozygous for Met. This mouse strain (Mx-cre x Met+/-) was then 
intercrossed with the conditional Met KO mouse model, so that all offsprings carried 
the floxed Met gene on the one allele and the Met WT or the classical Met KO gene 
on the other allele (Figure 11). To induce efficient excision of the single floxed Met 
allele, mice were intraperitoneally (i. p.) injected five times with polyinosinic/ 
polycytidylic acid (pI:pC). Mice with the Metflox/+ genotype result in Met WT 
phenotype, and mice with the Metflox/- genotype in Met-deficient (Met KO) phenotype. 
Additional intravenious injection of LPS prior to pI:pC injection was used to promote 
turn-over of LC  (Roake et al., 1995).  
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Figure 11. Breeding strategy to obtain conditional Met-deficient (Met KO) mice and 
Met wild-type (Met WT) littermates. A conditional Met KO model generated by Borowiak et 
al. was employed. Met-deficiency was achieved by conditional deletion of loxP-flanked exon 
15 encoding the ATP binding domain of Met kinase (Borowiak et al., 2004). Flt3+ CD11b+ 
progenitors were generated in vitro from BM. After 3 days of expansion with defined 
cytokines, the cells were genotyped to show excision efficiency.     
 
At least 2 weeks after the last injection, the mice were used for in vivo assays. PCR 
analyses revealed, that after LPS and pI:pC treatment of mice, the floxed allele of 
these mice was almost completely excised in all haematopoietic cells of the BM. 
From these HSCs, also Flt3+ CD11b+ progenitors were generated for in vitro assays 
(Figure 11). 
 
3.2.2. Mx-cre-mediated gene excision 
3.2.2.1. Mx-cre-mediated gene excision in GFP reporter mice  
To estimate the efficiency of the Cre recombination in peripheral DCs, the reporter 
mouse strain STOCK Tg(CAG-Bgeo/GFP)21Lbe/J, which expresses GFP after Cre-
mediated excision, was used (Novak et al., 2000). This GFP reporter mouse strain 
was first intercrossed with Mx-cre strain to obtain Mx-cre x GFP21-loxP mice. Mx-cre 
x GFP21-loxP mice were injected 5 times i.p. to mutate the floxed GFP allele. First, 
expression of Cre recombinase was examined by Western blot analysis. There, the 
injection of pI:pC into Mx-cre mouse strains led to a successful  production of Cre 
recombinase (Figure 12 A). To quantify Mx-cre-mediated gene excision in peripheral 
DCs, DCs in the spleen were additionally analysed for GFP expression by flow 
cytometry. There, GFP expression was found in almost 50% of all splenocytes 
(Figure 12 B, upper panel) and almost all CD11c+ DCs (~93%) (Figure 12 B, lower 
panel).  
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Figure 12. Efficiency of the Mx-cre system for recombination of floxed allels in 
peripheral DCs. (A) pI:pC induced production of Cre recombinase was analysed by 
Western blotting. Protein lysates were obtained from spleen of a Mx-cre mouse injected with 
pI:pC 5 times i. p. and from in vitro generated DCs derived from Met WT and Met KO BM. In 
vitro generated BMDCs infected with Cre-adenovirus were used as positive control, and 
protein lysates of the WT spleen as negative control. (B) To analysis the efficiency of the Mx-
cre system for recombination of floxed allels in peripheral DCs, Mx-cre x GFP21-loxP 
reporter mice were injected 5 times i. p. each with pI:pC. Expression of Cre recombinase 
results in GFP expression. Total splenocytes (upper panel) and density gradient-purified 
mononuclear cells (MNCs) from spleen (lower panel) were analysed for GFP expression by 
flow cytometry.  
 
3.2.2.2. Met deletion on genomic level 
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As described before, almost all peripheral DCs in the spleen were affected by Cre-
mediated recombination in the GFP reporter mouse strain. In the next step, Mx-cre x 
Metflox/- and Mx-cre x Metflox/+ were injected with pI:pC, to obtain mice with the Met 
KO and Met WT phenotype, respectively. In order to investigate, whether cells in 
spleen and in BM have not responded to pI;pC, deletion of Met exon 15 was 
analysed by genotyping. DNA from Met KO and Met WT mice was isolated from 
spleen, whole BM and from BM-derived Flt3+ CD11b+ progenitors, which can give 
rise to DCs in vitro and in vivo. PCR analysis revealed complete excision of floxed 
Met in DC progenitors of Met KO and Met WT BM (Figure 13). In contrast, not all 
cells in spleen and in BM showed Met deletion, which is in line with results obtained 
from Mx-cre x GFP21-loxP mice (Figure 12 B). 
 
 
Figure 13. Efficiency of Mx-cre system in Metflox mouse on genomic level. Genomic 
DNA was extracted from tail cuts, density gradient-purified mononuclear cells (MNCs) from 
spleen, whole BM, and Flt3+ CD11b+ progenitors after 3 days in culture from Met KO and 
Met WT mice. Using PCR, the genomic DNA was examined for Mx-cre-induced Met deletion. 
Detection of Mx-cre was used as loading control. WT-Met primer pair detects both WT and 
floxed alleles. 
 
3.2.2.3. Met deletion on mRNA level 
From in vitro amplified Flt3+ CD11b+ progenitors of pI;pC-injected Met WT and Met 
KO mice, DCs were generated with GM-CSF (Hieronymus et al., 2005). From in vitro 
DCs, RNA was isolated, and reverse-transcribed. Expression of Met WT gene and 
exon 15-deleted gene was analysed by semi-quantitative RT-PCR using a primer 
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pair, of which the forward primer binds upstream and the reverse primer downstream 
of exon 15, so that the mRNA sequence around exon 15 could be amplified.  
In Met WT mice (Mx-cre x Metfl/+), a WT allele and an exon 15-deleted Met allele, 
which had been originally a floxed allele before excision, could be detected. In 
contrast, in Met KO DCs (Mx-cre x Metfl/-) only exon 15-deleted mRNA was 
detectable. (Figure 14). The absence of WT mRNA in DCs of the conditional KO 
confirms highly effective gene recombination of floxed Met allele in DCs. 
  
 
Figure 14. Efficiency of Mx-Cre system in Metflox mouse on mRNA level. DCs were 
generated from Met WT and KO BM according to previously described protocol (Hieronymus 
et al., 2005). During differentiation, DCs were harvested at different time points, and 
analysed for mRNA expression of Met exon 15, Met, Tnfa, β-Tubulin (Tubb4). Detection of 
β-Tubulin expression was used as loading control. 
 
3.2.2.4. Met deletion on protein level  
In the conditional Met KO mouse model, exon 15 of Met is flanked by loxP sites. 
Exon 15 encodes the intracellular ATP-binding domain of Met, which is essential for 
its kinase function (Borowiak et al., 2004). Exon 15 has a length of 81 base pairs, 
and excision results in no frame shift. Thus, also cells with excised gene express Met 
with all extracellular domains, but with exon 15-deleted intracellular domains lacking 
kinase activity. Met WT and Met KO cells can therefore be not distinguished by Met 
surface expression analysis (see 3.5.1.2). 
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3.3. DC migration assays 
3.3.1. Ex vivo migration assay 
Functional expression of Met in LCs and dermal DCs and induction of LC emigration 
by SF/HGF provided a strong evidence for the role of Met in LC/DC mobilization 
(Kurz et al., 2002). Therefore, the emigration of Met deficient LCs from ear skin 
biopsies after treatment with pro-inflammatory stimuli, such as TNF-α and LPS, or 
SF/HGF was investigated. In order to allow quantification of LC migration from skin 
of induced conditional Met KO, LC population density in the epidermis of Met KO and 
Met WT under steady-state conditions was analysed. For that reason, epidermal 
sheets from Met KO or Met WT mice were stained for MHC class II and subjected to 
immunofluorescence microscopy. Epidermal tissues of Met KO and Met WT showed 
similar number of LCs (Figure 15). 
 
 
Figure 15. LC density in Met WT and KO epidermis. LCs were stained with anti-MHC 
class II in freshly isolated Met WT and KO epidermis. Scale bars, 50 µm. 
  
Ear sheets of Met KO and Met WT were cultivated in RPMI medium containing LPS, 
TNF-α and SF/HGF, respectively (Figure 16 C). After 3 day of incubation, the 
emigrated LCs and dermal DCs were collected and analysed by flow cytometry 
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(Figure 16 A and B). In parallel, epidermal sheets were isolated from the cultivated 
ear biopsies, stained for LCs, and analysed by immunofluorescence microscopy 
(Figure 16 D).  
One of the characteristics of emigrated LCs and dermal DCs was high expression of 
Met (Figure 16 A). Whichever stimulus the ear sheets were treated with, the LC/DC 
emigration from skin was significantly dependent from Met. In Met WT ear sheets, 
stimulation of with LPS, TNF-α, and SF/HGF led to the enhanced numbers of 
emigrated LCs and dermal DCs. In Met deficient ear sheet, the number of emigrated 
DC after treatment with LPS, TNF-α, or SF/HGF were comparable to that without 
additional stimuli (Figure 16 B). In parallel, the epidermis was stained for MHC class 
II to analysed whether LCs remained in the tissue. After treatment with any of all 
stimuli, WT epidermis showed low density of LCs, whereas KO epidermis contained 
high number of retained LCs. Numbers of emigrated cells reciprocally mirrored the 
number of stained cells, which remained in the epidermis after incubation. (Figure 16 
D). 
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Figure 16. Ex vivo migration assay Met KO and Met WT ear sheet explants were 
cultivated in culture media containing pro-inflammatory stimui TNF-α, LPS, or SF/HGF at the 
air-fluid interface for 3 days, as described by Larsen et al(Larsen et al., 1990). (A) LCs and 
dermal DCs, which had migrated into the culture media were analysed for Met expression. 
(B - D) Ear biopsies were analysed after 3 day of cultivation. (B) LCs and dermal DCs 
emigrating from ear sheet explants into medium containing different stimuli were counted by 
FACS. All bar diagrams show mean values +SD from four mice per group; *p < 0.05 
(Student’s t-Test) (C) Schematic representation of ex vivo migration assay with ear skin 
explants (D) For detection of LCs, epidermis were stained for MHC class II. Scale bars, 50 
µm 
 
Met WT DCs emigrated from skin and retained Met KO DCs upon LPS treatment, 
were analysed for their surface marker profile to gain information about their 
activation status. Activated DCs are known to up-regulate a defined set of co-
stimulatory molecules and chemokine receptors.  
Met KO DCs retained in the epidermis showed up-regulated expression of co-
stimulatory molecules and Met upon LPS treatment (Figure 17). The surface marker 
profile of retained Met KO DCs was identical to that of emigrated Met WT DCs. 
Interestingly, Met KO DCs also up-regulated the chemokine receptor CCR7 upon 
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activation, which is essential for the migration of skin DCs towards the LN (Forster et 
al., 2008; Ohl et al., 2004; Sallusto et al., 1999). . 
 
 
Figure 17. Flow cytometry analysis of LCs/DCs from ear skin explants. Phenotypic 
characterization of DCs that have emigrated from skin tissue in Met WT mice (upper panel) 
or have retained in skin tissue of Met KO mice after LPS treatment for 3 days (lower panel). 
After 3 days in culture, single cell suspensions from skin tissue or emigrated DCs in culture 
supernatants were examined by flow cytometry for surface antigen expression as indicated 
(filled histograms). Open grey histograms, isotype controls. 
 
3.3.2. In vivo migration of DCs 
3.3.2.1. Skin DC migration assay 
Next, in vivo migration kinetics of LCs and dermal DCs in Met KO and Met WT mice 
from skin tissue towards skin draining LNs during inflammation were examined. To 
assess the migration capacity of LCs and dermal DCs in vivo, a mouse painting 
assay was performed with the fluorescence dye FITC (Allan et al., 2006; Randolph et 
al., 2005). Met KO and Met WT mice with comparable LC density (Figure 15) were 
painted on the abdomen with FITC dissolved in 1:1 acetone/dibutyl phthalate. The 
presence of FITC-carrying skin-derived migratory DCs in the skin draining inguinal 
and brachial LNs, and mesenteric LNs were analysed 24 h, 48 h, and 72 hours later 
by flow cytometry. Brachial LNs are far distant from the site of FITC painting, and 
therefore direct labelling of LN-resident DCs by passively transported FITC through 
lymphatics was minimized (Allan et al., 2006; Randolph et al., 2005). In parallel, non-
draining mesenteric LNs were analysed as control. 
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When FITC solution was epicutaneously applied to Met WT mice, skin DCs with high 
expression of MHC class II effectively migrated into brachial LNs. In contrast, in Met 
KO mice, FITC-positive skin migratory DCs were almost absent in brachial LNs over 
all time points (Figure 18 A and B). 
 
 
 
Figure 18. FITC painting of Met KO and Met WT mice. Met KO and Met WT mice were 
painted with 100 µl of 0.5% FITC solved in 1:1 acetone/dibutyl phthalate on shaved 
abdomen. Brachial and mesenteric LNs were dissected. LNs were dissociated to single cell 
suspension and stained for flow cytometry. Cells were gated either (A) for all lymphocytes or 
(B) for CD11c+ DCs in the LNs. 
 
Next, the skin draining inguinal LNs were also analysed, which were located closer 
to the site of FITC painting than brachial LNs. Based on spatial advantage, inguinal 
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LNs can contain more resident DCs that have captured free FITC molecules 
passively transported via lymphatics than brachial LNs. Therefore, we used less 
amount of FITC for skin painting than in the analysis of brachial LNs. Here, again a 
distinct reduction of LC/DC migration into inguinal LNs in Met KO mice compared to 
that in Met WT mice could be observed over all time points. (Figure 19 A and B).  
 
 
 
Figure 19. FITC painting of Met KO and Met WT mice. Met KO and Met WT mice were 
painted with 50 µl of 0.2% FITC solved in 1:1 acetone/dibutyl phthalate on shaved abdomen. 
Inguinal and mesenteric LNs were dissected. LNs were dissociated to single cell suspension 
and stained for flow cytometry. Cells were gated either (A) on all lymphocytes or (B) on 
CD11c+ cells in the LNs. 
 
3.3.2.2. Contact hypersensitivity studies 
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FITC-labelled skin DCs were shown to migrated to skin draining LNs in a Met-
dependent manner. To further assess physiological consequences of Met deficiency 
in DCs, Met deficient LCs and DCs were examined for the ability to sensitize mice for 
the chemical haptens FITC and DNFB, which leads to hypersensitivity reactions after 
a second contact. 
First, Met KO and Met WT mice were painted with FITC in 1:1 acetone/dibutyl 
phthalate on the shaved abdomen for sensitization. Contact hypersensitivity (CHS) 
was elicited by applying FITC to ear skin of the mice 5 days after sensitization. To 
determine the CHS reaction, the thickness of the ear swelling was measured. FITC 
in 1:1 acetone/dibutyl phthalate was applied to one mouse ear, and the solvent only 
to the other mouse ear. The ear swelling of Met WT mice was more pronounced than 
that of Met KO mice. Treatment with acetone/dibutyl phthalate alone also led to a 
basal ear swelling because of inducing cutaneous inflammation of mouse skin 
(Figure 20).  
 
 
Figure 20. CHS reactions in response to FITC in Met KO and Met WT mice. Met KO and 
Met WT mice were sensitized by applying 0.5% FITC in acetone/dibutyl phthalate solution 
on their shaved abdomen. Basal ear thickness was measured five days after initial 
immunization before applying 1 % FITC solution on both ventral and dorsal skin surfaces 
(+FITC) of the right ears to elicit a CHS reaction. Left ears were treated with solvent only (-
FITC). Ear thickness was measured 24 h after challenge, and increase in ear swelling in Met 
KO and Met WT mice was analysed. Bar diagram shows mean values + SD from five mice 
per group. *p < 0.05. 
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To circumvent the basal ear swelling caused by the skin-irritating solvent, CHS 
response in Met KO and Met WT was next examined using DNFB. DNFB does not 
require an irritating solvent for sensitization and thus was solved in acetone/olive oil. 
Met KO and Met WT mice were sensitized by applying DNFB on the abdominal skin 
on two days. CHS was elicited by re-exposing the mice to DNFB on ear skin 5 days 
after the last sensitization. To enumerate the CHS reaction, the thickness of the ear 
swelling was measured. DNFB was applied to one mouse ear, and solvent only to 
the other mouse ear. Met WT mice showed severe ear swelling in response to 
DNFB, which reflected strong CHS response. In contrast, ear swelling reaction and 
thus CHS response was significantly reduced in Met KO mice. (Figure 21).  
 
 
Figure 21. CHS reactions in response to DNFB in Met KO and Met WT mice. Met KO 
and Met WT mice were sensitized two days by applying 0.5% DNFB in acetone/olive oil 
solution on their shaved abdomen. Basal ear thickness was measured five days after initial 
immunization before applying 0.2 % DNFB solution on both ventral and dorsal skin surfaces 
(+DNFB) of the right ears to elicit a CHS reaction. Left ears were treated with solvent only (-
DNFB). Ear thickness was measured 24 h after challenge, and increase in ear swelling in 
Met KO and Met WT mice was determined. Bar diagram shows mean values + SD from five 
mice per group. *p < 0.004.  
 
Hence, it was addressed whether inhibition of Met signalling under normal 
physiological conditions could repress CHS reactions. The shaved abdominal skin of 
C57Bl/6 WT mice was pre-treated with the Met inhibitor SU11274 for 30 min before 
applying DNFB. CHS responses were elicited and analysed as before. The results 
revealed that pharmacological inhibition of Met signalling was able to significantly 
diminish the ear swelling reactions (Figure 22).   
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Figure 22. CHS reactions in response to DNFB after Met inhibitor treatment in WT 
mice. Met WT mice were pre-treated with Met inhibitor (SU11247) 30 min prior to 
sensitization with 0.5% DNFB in acetone/olive oil solution on their shaved abdomen. Basal 
ear thickness was measured five days after initial immunization before applying 0.2 % DNFB 
solution on both ventral and dorsal skin surfaces (+DNFB) of the right ears to elicit a CHS 
reaction. Left ears were treated with solvent only (-DNFB). Ear thickness was measured 24 h 
after challenge, and increase in ear swelling was determined. Bar diagram shows mean 
values + SD from five mice per group. *p < 0.03. 
 
 
3.4. LC repopulation of skin epidermis 
SF/HGF was demonstrated to induce LC emigration from skin, and Met to be 
indispensable for emigration of LCs from skin epidermis. In the next step, BM 
chimeric mice were generated to determine whether Met has also an important role 
in LC development, precursor migration into peripheral tissue and consequently in 
LC repopulation of the epidermis. Met KO and Met WT CD45.2 BM cells were 
transplanted into lethally irradiated CD45.1 mice, respectively. At 7 weeks post 
transplantation, the mice were exposed to high-dose UV light depleting LCs from 
skin epidermis to allow reconstitution of LCs from BM-derived precursors. Further 9 
weeks later, the ear epidermis was analysed for donor and recipient-derived LCs. 
Epidermis skins were stained for MHCII and CD45.1. Co-localization of CD45.1 and 
MHCII indicated recipient-derived LCs, and cells positive for MHCII only represented 
donor-derived LCs (Figure 23). 
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Figure 23. Schematic representation of experimental outline to determine LC 
repopulation by derived Met KO and Met WT precursors. Repopulation of LCs in 
epidermal sheets after UV irradiation was examined by fluorescence microscopy.   
 
Engraftment of BM and the development of donor-derived DCs were examined by 
flow cytometry 2 weeks and 16 weeks after transplantation of Met KO and Met WT 
BM, respectively. At 2 weeks post-transplantation, engraftment of CD45.2+ donor 
cells from both Met WT and Met KO was detectable in BM as well as in spleen. DCs 
had arisen from both Met WT and Met KO transplanted BM at similar rates (Figure 
24 A).  
Two weeks after transplantation, the majority of peripheral T cells was still of 
recipient origin, but steadily replaced by donor-derived T cells from both Met WT and 
Met KO BM. Thus, the development of T cells was not dependent on functional Met 
protein.  
16 weeks after BM transplantation, when recipient mice were examined for LC 
chimerism, BM and spleen were analysed again for origin of haematopoietic 
progenitor cells, DCs and T cells. The results showed that the development of 
haematopoietic progenitor cells, DCs and T cells from both Met WT and Met KO 
donor BM was identical (Figure 24 B).  
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Figure 24. Engraftment of transplanted Met WT and Met KO BM. Data show engraftment 
of Met WT and Met KO donor cells and development of DCs and T cells (A) 2 weeks and (B) 
16 weeks after BM transplantation. CD45.2-positive staining indicates cells of donor origin. 
Red boxes indicate CD34+ c-Kit+ CD11b-low self-renewing (short-term repopulating) HSC 
(ST-HSC). 
 
At 9 weeks post-UV irradiation, almost all LCs (> 94%) in skin were of donor origin. 
The reconstitution of LCs by Met KO BM was equivalent to that by Met WT BM. The 
observation, that LC chimerism took place after transfer of CD45.2 Met KO into 
CD45.1 Met WT, led to the conclusion, that Met was not necessary for LC 
reconstitution and, accordingly, also not for migration of LC precursor into the 
epidermal tissue (Figure 25 A and B).  
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Figure 25. LC repopulation of skin epidermis. Epidermal sheets from CD45.1+ recipient 
animals transplanted with Met WT or Met KO BM were stained for MHC class II (red) and 
CD45.1 (green) expression and with DAPI (blue). (A) Arrowheads indicate CD45.1+ MHC 
class II- host cells. Arrows denote CD45.1+ MHCII class II+ host cells considered as host 
LCs. Representative images are shown. Scale bars, 50 µm. (B) Bar diagram represents the 
number of LCs per mm2. Data are the means +SD of 3 animals per group. (C) Excision of 
floxed Met alleles in engrafted BM. Genotyping was done by PCR for floxed (fl) or wild-type 
(WT) Met alleles.  
 
Using PCR analysis, the donor BM was tested for Met excision before and after 
transplantation. CD45.1 recipient mice developed CD45.2+ LCs after UV irradiation, 
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but no floxed alleles were detectable in the BM of recipient animals. Met WT allele 
detectable in recipients of Met KO BM were of host origin (Figure 25 C). 
 
 
3.5. In vitro generation and functional characterization of Met 
KO DCs  
3.5.1. Generation of GM-CSF-derived BMDCs (GMDC) 
3.5.1.1. Met and SF/HGF expression during in vitro DC development 
Transcriptional analysis of Met expression during DC development was examined 
with in vitro generated GMDC. To generate DCs with GM-CSF in vitro, Flt3+ CD11b+ 
progenitors were first expanded with cytokine cocktail consisting of SCF, hyperIL-6 
(Fischer et al., 1997), IGF-1, Flt3-ligand, GM-CSF and dexamethasone for 7 days 
and subsequently differentiated into DCs with GM-CSF (Hieronymus et al., 2005). 
During differentiation, cells were harvested for semi-quantitative RT-PCR analysis 
(Figure 26 A).  
When all DCs expressed intermediate levels of MHC class II after 8 – 12 days of 
differentiation, GMDCs were further activated with LPS or TNF-α. Interestingly, Met 
and its ligand SF/HGF were expressed already in Flt3+ CD11b+ progenitors 
(Hieronymus et al., 2008; Merad et al., 2008), but the expression level of Met and 
SF/HGF both decreased during early stages of DC development (day 0 to day 7 of 
differentiation). Unlike SF/HGF, Met expression was up-regulated again at later 
stages. With maturation of GMDCs by LPS stimulation, a further elevation of Met 
expression was detected (Figure 26 B).   
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Figure 26. Transcriptional regulation during in vitro DC development and activation (A) 
Expression of Met, Hgf/SF, Tnfa, and Relb during differentiation of GMDCs from BM-derived 
Flt3+ CD11b+ progenitor cells (left panel) and after activation of differentiated GMDCs with 
LPS for 16 h (right panel). Detection of β-Tubulin (Tubb4) expression was used as loading 
control. (B) Time course analysis of Met expression in GMDCs after LPS treatment for the 
indicated times. Expression of Met was analysed by RT-PCR using 25 cycles and 35 cycles 
for amplification. Detection of Gapdh expression was used as loading control.  
 
3.5.1.2. Surface marker analysis of Met-deficient GMDCs 
To investigate molecular mechanism of Met signalling in DCs, Met WT and Met KO 
GMDCs were generated in vitro, and comparative analyses were performed.  
First, the surface marker profile of GMDCs was examined by flow cytometry to 
investigate DC phenotype. In addition, the surface marker profile of DCs provides 
information about the activation status of DCs. There were no differences in the 
surface marker profile between immature GMDCs from Met WT and those from Met 
KO mice. There were also no differences between mature GMDCs from Met KO and 
those from Met WT mice after stimulation with LPS (Figure 27 A) or TNF-α (Figure 
RESULTS 77 
 
27 B). Activation of Met WT and Met KO GMDCs caused efficient up-regulation of 
MHC class II and co-stimulatory molecules. Met protein was detected on Met WT 
and Met KO GMDCs both at low levels and was up-regulated upon activation. 
Noteworthy, Met KO GMDCs still expressed extracellular domain of Met, since the 
excised exon 15 has 81 base pairs and is located in the intracellular domain of the 
protein (Borowiak et al., 2004). Thus, Met surface expression was not supposed to 
reflect inefficient excision in GMDCs of Met KO mice as determined by genotyping 
(Figure 25 C). Marker profile of mature Met WT and Met KO GMDCs was also 
virtually identical to that of emigrated and retained DCs of Met WT and Met KO in 
skin explant assays (Figure 17). Met WT and Met KO GMDCs also expressed the 
chemokine receptor CCR7, which is essential for the migration of skin DCs towards 
LN (Forster et al., 2008; Ohl et al., 2004; Sallusto et al., 1999) (Figure 27). 
 
 
 
Figure 27. Surface antigen profile of Met WT and Met KO GMDCs. DCs were generated 
from Met WT and Met KO BM and examined by flow cytometry for surface antigen 
expression as indicated (filled histograms). Open blue histograms show surface antigen 
expression after stimulation with (A) LPS (blue) or (B) TNF-α (red) for 24 h.; open gray 
histograms, isotype controls. 
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3.5.1.3. SF/HGF-signalling in Met-deficient GMDCs 
In vivo, Met was revealed as functionally expressed in DCs (Kurz et al., 2002). Met 
signalling after ligand binding confers mitogenic, morphogenic and motogenic activity 
to various cells. Aberrant and normal Met kinase signalling has shown to activate 
different downstream signalling pathways. Among these downstream targets, MAPK 
activation was found in the majority of cells (Birchmeier et al., 2003; Trusolino and 
Comoglio, 2002). Using Western blot analysis, Met-signalling deficiency in Met KO 
DCs was examined by analyzing MAP kinase activation in response to SF/HGF 
stimulation in immature (Figure 28 A) and mature DCs (Figure 28 B). Results 
showed a fast and sustained Erk1/2 activation particularly of Erk1/p44 MAP kinase. 
In contrast, Met KO DCs were SF/HGF-signalling incompetent as no Erk1/2 
activation was observed. In immature DCs, which comprise a heterogeneous pool of 
proliferating and maturing cells, a basal level of Erk1/2 activation was detected. In 
LPS-stimulated cells, the basal level of Erk1/2 activation was eradicated presumably 
by a negative feedback mechanism of LPS-mediated Erk1/2 activation (Figure 28 A 
and B). 
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Figure 28. Western blot analysis of SF/HGF induced signalling. GMDCs were generated 
from Met WT and Met KO BM and (A) immature DCs and (B) LPS-activated DCs were 
stimulated with SF/HGF for the indicated times. Protein lysates were analysed for total and 
phosphorylated ERK1/2 (pErk1/2) expression. Detection of β-actin was used as loading 
control. 
 
3.5.1.4. Impact of Met-signalling on DC development 
SF/HGF is a differentiation factor for various cells. In human system, SF/HGF was 
described as a DC poietin at a concentration of 20 ng/ml (Ovali et al., 2000; Rutella 
et al., 2006a; Sonmez et al., 2007). To test, whether SF/HGF has a similar role in 
mouse system, in vitro amplified Flt3+ progenitor cells and BM cells were cultured 
with SF/HGF using a concentration from 20 ng/ml up to 100 ng/ml. Neither the in 
vitro amplified Flt3+ CD11b+ progenitors according to the two-step protocol 
(Hieronymus et al., 2005), nor the heterogeneous cell population of the BM using the 
one-step protocol for DC development (Lutz et al., 1999) gave rise to DCs in 
response to SF/HGF. At the end of culture, there were only few viable cells, which 
did not have DC phenotype, e.g. no CD11c expression.  
Thus, to investigate the influence of SF/HGF on DC development, Met WT and Met 
KO DCs were generated according to the one-step and two-step protocols for DC 
differentiation with additionally supplemented 50 ng/ml SF/HGF. Since Met KO 
GMDCs are SF/HGF-signalling incompetent and DCs do not express SF/HGF, 
SF/HGF-treated Met KO GMDCs should be comparable to Met WT GMDC cultured 
without SF/HGF treatment (Figure 29 A, lower panel). 
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Met WT and Met KO GMDCs cultured with SF/HGF during differentiation showed 
same surface marker profile at the end of differentiation, which indicates, that 
SF/HGF has no impact on DC differentiation. When SF/HGF-treated cells were 
further stimulated with LPS, the activation of DCs was not attenuated (Figure 29 A).      
While long-term SF/HGF treatment did not result in any changes in surface marker 
profile of GMDCs, next short-term treatment of SF/HGF on differentiated GMDCs 
was assessed. Therefore, Met WT GMDCs were differentiated and activated with 
LPS or left immature. Mature and immature DCs were stimulated with SF/HGF for 16 
h and analysed for the surface marker profile by flow cytometry (Figure 29 B). Short-
term treatment of SF/HGF did not mature GMDCs (upper panel) and did not 
influence the surface marker profile of LPS-activated GMDCs (lower panel).  
 
 
 
Figure 29. Surface marker analysis of GMDC after SF/HGF stimuation. 1(A) GMDCs were 
generated with GM-CSF and 50 ng/ml SF/HGF in vitro from Met WT and Met KO BM. DCs 
were examined by flow cytometry for surface antigen expression as indicated (filled 
histograms). Open blue histograms show surface antigen expression after LPS stimulation. 
(B) GMDCs were generated with GM-CSF from Met WT BM. Half of the culture was further 
treated with 1µg/ml LPS (lower panel). DCs were examined by flow cytometry for surface 
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antigen expression as indicated (filled histograms). Open green histograms show surface 
antigen expression 16 h after SF/HGF stimulation; open gray histograms, isotype controls. 
 
3.5.1.5. Cytokine production in Met-deficient GMDCs 
Mature DCs secrete a variety of cytokines that are involved in activation and 
recruitment of other immune cells, and also influence their own immune function in 
an autocrine/paracrine manner. Thus, cytokine production by DCs is counted as one 
of the most important immunofunctional properties of DCs. To further investigate for 
the influence of SF/HGF on immune functions of DCs, immature and mature Met WT 
and Met KO GMDCs were analysed for secretion of selected cytokines. Expression 
and secretion of IL-6, IL-10, IL-12p40, MCP-1 (CCL2), MIG, and TNF-α was 
analysed in response to LPS and/or SF/HGF treatment (Figure 30). IL-6, MCP-1, 
and TNF-α are pro-inflammatory cytokines activating and recruiting other immune 
cells of the innate immune system, which are secreted by DCs upon TLR activation 
(Akira et al., 1990; Brach and Herrmann, 1992; Matsushima et al., 1989; Tracey and 
Cerami, 1993). MIG is a chemoattractant for NK cells and stimulated T cells, which is 
secreted in response to IFNs (Farber, 1993; Mahalingam et al., 2001). IL-10 is 
considered as an anti-inflammatory cytokine, responsible for the inhibition of Th1 
response and differentiation of regulatory T cells. IL-12p70 is a pro-inflammatory 
cytokine and is involved in polarization of naïve CD4+ T cells towards Th1 (Belkaid, 
2007; McGuirk and Mills, 2002; Rutella et al., 2006b). The culture supernatants of 
SF/HGF-treated immature and mature DCs were collected 24 h (Figure 30, left panel) 
or 16 h (Figure 30, right panel) after SF/HGF treatment and subjected to cytometric 
bead assay (CBA) for cytokine analysis. 
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Figure 30. Cytokine secretion by Met WT and Met KO GMDCs. Culture supernatants of 
Met WT and Met KO GMDCs were harvested 16 h after LPS treatment and 24 h (left panel) 
or 16 h (right panel) after additional SF/HGF treatment. Cytokine secretion was analysed by 
CBA. Data shown are from two independent experiments. 
 
3.5.1.6. Antigen-specific T-cell activation by Met-deficient GMDCs  
Another important immune function of DCs is the activation of naïve T cells. DCs are 
the most potent antigen-presenting cells and antigen-specific activated T cells 
undergo clonal expansion. 
First, the T-cell activation property of immature and LPS-activated Met KO GMDCs 
was examined and compared to that of Met WT GMDCs. Activation of Met WT and 
Met KO DCs by LPS caused efficient up-regulation of MHC class II and co-
stimulatory molecules. There was no difference in the capacity of both Met WT and 
Met KO GMDCs to activate antigen-specific naïve T cells (Figure 31 A).  
SF/HGF has been described to induce development of tolerogenic DCs (Okunishi et 
al., 2005; Rutella et al., 2006a; Rutella et al., 2006b). To study the influence of 
SF/HGF on antigen presentation property of DCs, Met WT and Met KO GMDCs with 
and without LPS activation were additionally stimulated with SF/HGF. There was no 
difference in the capacity of both Met WT and Met KO GMDCs after SF/HGF 
stimulation to activate antigen-specific naïve T cells Here again, a comparable 
increase in T-cell activation by Met WT and Met KO GMDCs after LPS activation 
was observed (Figure 31 B).    
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Figure 31. Antigen-specific T-cell activation by Met-deficient GMDCs. CD4+ T cells from 
OT-II mice were co-cultured with OVA peptide-pulsed GMDCs from Met WT and Met KO 
mice at various ratios. Antigen-specific activation of CD4+ T cells was analysed by [3H]-
thymidine incorporation in DC/T cell co-cultures. (A) GMDCs and T cells were co-cultured 
without SF/HGF stimulation of DCs. (B) GMDCs were stimulated with SF/HGF for 24 h prior 
to T cell co-culture. Results (mean triplicate values ±SD) from one representative out of 
three individual experiments are shown.   
 
3.5.2. Met expression of in vitro generated LC-like cells and tolerogenic 
BMDCs 
Next, DC culture condition was modified by addition of TGF-β that promotes 
differentiation of Langerin-expressing LC-like cells and tolerogenic DCs in vitro to 
study their Met expression. TGF-β is known to be essential for LC development, as 
evidenced by TGF-β-deficient mice lacking LCs (Kaplan et al., 2007). In skin, TGF-β 
is expressed in steady-state and under inflammatory conditions and has been shown 
to promote development of tolerogenic DCs (Morelli and Thomson, 2007). 
Tolerogenic DCs are described to present antigen to antigen-specific T cells, but fail 
to deliver adequate co-stimulatory signals for effector T-cell activation and 
proliferation (Morelli and Thomson, 2007). DC tolerogenicity is neither specific to DC 
subpopulations nor restricted to the immature status of antigen-presenting cells. In 
vitro, tolerogenic DCs are generated from BM precursors and become tolerogenic 
through exposure to specific  cytokines, growth factors or pharmacological 
mediators as VD3 (Griffin et al., 2000; Penna and Adorini, 2000). Langerin-
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expressing LC-like cells were generated using TGF-β, and development of 
tolerogenic GMDCs was induced using TGF-β or VD3.  
 
 
 
 
Figure 32.  Surface marker analysis of GMDC cultured in presence of TGF-β. BMDCs 
were generated with GM-CSF in vitro from Met WT in presence of TGF-β at different 
concentrations. Terminally differentiated DCs were examined by flow cytometry for surface 
antigen expression as indicated. (A) Data showing yields of Langerin-expressing LC-cells 
and Met expression according to TGF-β concentration. (B and C) DCs were cultured in 
presence of (B) 5 ng/ml TGF-β or (C) 10 ng/ml TGF-β (open orange histograms) or in 
absence of TGF-β (filled histograms). DCs were stimulated with LPS at the end of 
differentiation (lower panels; filled blue histograms). Filled black histograms show controls 
without LPS treatment (upper panels). 
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First, DC medium was supplemented with TGF-β at a concentration of 5 ng/ml during 
the whole differentiation procedure. This concentration was appropriate to generate 
cells with a tolerogenic phenotype and additionally to derive Langerin expressing LC-
like cells. Interestingly, all CD11c+ cells showed high levels of Met compared to 
untreated cells (Figure 32 A and B). When TGF-β concentration was increased to 10 
ng/ml, almost all GMDCs showed a tolerogenous phenotype and no up-regulation of 
co-stimulatory molecules.  In presence of 10 ng/ml TGF-β, the Met expression levels 
were lower than in the presence of 5 ng/ml TGF-β (Figure 32 C).  
Next, in vitro tolerogenic DCs were generated with short-term VD3 treatment for 24 h 
following usual GMDC differentiation protocol. When differentiated DCs were treated 
with VD3 prior to the LPS stimulation, DCs were not able to up-regulate co-
stimulatory molecules in response to LPS. However activation of VD3 treated 
GMDCs with LPS leads to an elevation of Met expression (Figures 26 and 27). As 
reported previously, VD3 inhibits DC maturation by inhibition of NF-κB signalling, 
(D'Ambrosio et al., 1998; Dong et al., 2003; Xing et al., 2002; Yu et al., 1995; 
Goncharenko N. et al., unpublished data). Thus, NF-κB signalling is not required for 
activation-induced up-regulation of Met expression (Figure 33). 
 
 
Figure 33. Surface marker and Met expression analysis of tolerogenic GMDC. GMDCs 
were generated with GM-CSF in vitro from Met WT BM. When differentiated, DCs were pre-
treated with VD3 for 24 h and then stimulated with LPS (lower panel). DCs were examined 
by flow cytometry for surface antigen expression as indicated (filled histograms). Filled black 
histograms show surface antigen expression before treatment with VD3 and LPS, filled blue 
histograms after treatment. 
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3.5.3. Generation of Flt3-derived BMDC (FLDC) 
Flt3-ligand is known as an essential factor in DC homeostasis (Merad and Manz, 
2009). With Flt3-ligand, three distinct DC subpopulations can be generated in vitro 
that are functionally, morphologically, developmentally and phenotypically equivalent 
to steady-state DCs in lymphatic organs comprising pDCs, CD8α + cDC and CD8α - 
cDC. (Naik et al., 2005; Xu et al., 2007). 
To generate FLDCs with Flt3 in vitro, Flt3+ CD11b+ progenitors were first expanded 
with a cytokine cocktail consisting of SCF, hyperIL-6 (Fischer et al., 1997), IGF-1, 
Flt3-ligand for 5-7 days and subsequently differentiated into DCs with Flt3-ligand 
only (Felker et al., 2010). Terminally differentiated FLDCs were stained for MHCII, 
Met and surface markers specific for pDC, CD8α- and CD8α-like DC. In vitro 
generated CD8α-like immature DC do not express CD8α surface antigen, but are 
readily detectable as CD24-high cells (Figure 34 A and B). 
Like Met WT Flt3+ CD11b+ progenitors, Met KO Flt3+ CD11b+ progenitors were 
able to give rise to all FLDC subpopulation (Figure 34 B). It was noticed that in 
contrast to low Met expression of pDCs in vivo (Figure 7), Flt3-ligand generated 
pDCs in vitro expressed very high levels of Met. Flt3-ligand generated cDCs are 
considered to represent lymphoid organ-resident cDCs (Shortman and Naik, 2007). 
Met expression in Flt3-ligand generated cDCs was equally low compared to 
lymphoid organ-resident cDCs (Figure 5 and 6). LPS activation of FLDCs did not 
lead to up-regulation of Met expression at least on protein level (Figure 34 A and B). 
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Figure 34 In vitro DC development with Flt3-ligand and Met expression in Met WT and 
Met KO FLDCs. DCs were generated with 50 ng/ml Flt3-ligand from Met WT and Met KO 
Flt3+ CD11b+ progenitors in vitro. DC supbpopulations were examined by flow cytometry for 
expression of Met and MHCII. Open red histograms show surface antigen expression of 
pDCs, open green histograms: CD8α-like DCs, open blue histograms: CD8α- DCs. 
 
 
3.6. Migration properties of Met-deficient GMDCs 
3.6.1. Migration towards chemokine gradients 
Next, the migratory functions of GM-CSF derived DCs from Met WT and Met KO BM 
was analysed in response to the chemokines CCL19/MIP3-beta/ELC and 
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CXCL12/SDF-1. The importance of the respective chemokine receptors CCR7 and 
CXCR4 for DC migration is well established and GMDCs express CCR7 and CXCR4 
(Alvarez et al., 2008; Randolph et al., 2005). Met WT and Met KO GMDCs showed 
no differenced in the expression of CCR7 (Figure 27). Chemotaxis of GMDCs in 
response to CCL19 and CXCL12 was analysed at first in Boyden chamber (transwell) 
assays using uncoated transmembrane inserts with 5 µm pore size. GMDCs were 
stimulated with LPS and SF/HGF before (Figure 35, left panel). No differences in the 
migratory activity of both Met WT and Met KO GMDCs were observed (Figure 35). 
  
 
Figure 35. Transwell migration assay using uncoated transmembrane. In the upper 
compartment of the Boyden chamber, 2 x 105 GMDCs stimulated first with LPS for 16 h and 
then with SF/HGF for 30 min were seeded. In the lower chamber, 100 ng/ml CCL19 or 
CXCL12 was added to the medium. Cell number in the lower compartment of the Boyden 
chamber was determined after 90 min by flow cytometry. Data show mean numbers of 
migrated DCs ± SD from three independent measurements.  
 
Next, transmembrane inserts were coated with an extracellular matrix (ECM) 
compound (Matrigel). Now, for transmigration of DCs towards a chemokine gradient 
active penetration by partial degradation and remodelling of the ECM barrier is 
required (Yen et al., 2008). Transmigration of DCs from Met WT and Met KO mice 
through ECM in response to CCL19 and CXCL12 was analysed and revealed a 
significant incapacity of Met KO GMDCs to pass the ECM barrier (Figure 36). 
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Figure 36. Transwell migration assay using Matrigel-coated transmembrane. Boyden 
chamber inserts were coated with Matrigel. In the upper compartment of the Boyden 
chamber, 2 x 105 GMDCs stimulated first with LPS for 16 h and then with SF/HGF for 30 min 
were seeded. In the lower chamber, 100 ng/ml CCL19 or CXCL12 was added to the medium. 
Cell number in  the lower compartment of the Boyden chamber was determined after 5 h by 
flow cytometry. Data show mean numbers of migrated DCs ± SD from three independent 
measurements.  
 
3.6.2. Regulation of matrix metalloproteinase (MMP) activities in GMDC 
by Met signalling 
3.6.2.1. Transcriptional regulation of MMPs 
Mature DCs in vivo express proteolytic enzymes to overcome ECM and basement 
membrane barrier e.g. in the skin (Alvarez et al., 2008). Particularly, maturing skin 
DCs up-regulate expression of secreted as well as membrane-bound forms of MMP 
2 and 9 (Ratzinger et al., 2002; Yen et al., 2008). Thus, GMDCs from Met WT and 
Met KO mice were analysed for MMP-2 and MMP-9 expression.  
Expression of both MMP-2 and MMP-9 was detectable in GMDCs from Met WT and 
Met KO mice. However, further stimulation with SF/HGF resulted in increased 
expression of MMP-9 only in Met WT GMDCs but not in DCs from Met KO mice, 
whereas no changes in MMP-2 expression were observed. MMP-9 up-regulation 
was not detectable until 16 h post-stimulation. The transcriptional regulation of MMP-
9 was quite delayed for the effect of SF/HGF stimulation on GMDCs in the 
transmigration assay, where transmigration through ECM occurred in less than 5 
hours (Figure 37).   
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Figure 37. Kinetics of Mmp9 and Mmp2 expression in GMDCs stimulated with SF/HGF. 
DCs were generated in vitro from the BM of Met WT and Met KO mice and activated with 
LPS for 24 h prior to stimulation with SF/HGF. Expression of Mmp9 and Mmp2 in DCs was 
analysed by RT-PCR after indicated times of SF/HGF stimulation. Expression of Gapdh 
mRNA was used as control. 
 
3.6.2.2. Regulation of MMP activities 
A transcriptional regulation of MMP-9 according to SF stimulation could be detected. 
Corresponding protease activity was found in culture supernatants that further 
increased upon LPS activation (Figure 38). This observation, together with the 
constitutive expression of MMPs in Met WT and Met KO GMDCs and the additional 
late transcriptional response of MMP-9 expression to SF/HGF stimulation of Met WT 
GMDCs in comparison to observed migration kinetics in vitro (Figure 37) and in vivo 
(Figures 5, 18 and 19) indicate additional regulatory mechanisms of MMP activity on 
post-transcriptional levels.  
 
 
Figure 38. Detection of MMP activities of soluble forms released by GMDCs from Met 
WT and Met KO mice to culture supernatants. GMDCs were differentiated from the BM of 
Met WT and Met KO mice and cultivated under serum-free conditions for 24 h hours prior to 
analyses for protease activities in culture supernatants. Proteolytic MMP activity in culture 
supernatants of immature DCs and LPS-matured DCs with (right panel) or w/o SF/HGF 
stimulation (left panel) as indicated was detected by zymography. Cell culture supernatants 
were loaded onto SDS polyacrylamid gel containing 0.1 % gelatine. After electrophoresis, 
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the gel was renatured, developed overnight (16 h) and stained with Coomassie Blue. White 
bands show protease activity. 
 
Therefore, MMP-2 and MMP-9 activities of the membrane-bound forms before and 
after LPS activation and SF/HGF stimulation were addressed. Native cellular lysates 
of Met WT and Met KO GMDCs were applied to zymography and revealed complete 
absence of both MMP-2 and MMP-9 activities on Met KO DCs (Figure 39). 
Furthermore, a complex regulation of MMP-activities in Met WT DCs by LPS and 
SF/HGF stimulation was observed that showed high MMP-2 and low MMP-9 
activities after activation by LPS. Additional SF/HGF stimulation upon DC activation 
resulted in elevated MMP-9 activity only, while protease activity of MMP-2 was 
abrogated (Figure 39). 
 
 
Figure 39. Detection of MMP activities of cell membrane-bound forms of Met WT and 
Met KO GMDC. Cell membrane-bound MMP activity was analysed by zymography. Cell 
lysates were loaded onto SDS polyacrylamid gel containing 0.1 % gelatine. After 
electrophoresis, the gel was renatured, developed overnight (16 h) and stained with 
Coomassie Blue. White bands show protease activity.  
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4. DISCUSSION 
In this work, the data propose a novel regulatory mechanism of LC/DC migration. 
Previous studies showed that SF/HGF can induce LC/DC emigration from skin (Kurz 
et al., 2002). In this work, a set of in vivo studies on DC emigration ranging from 
studying LC mobilization at peripheral sites to surveying accumulation of DCs in LNs 
has been performed employing a conditional Met knockout mouse model (Borowiak 
et al., 2004). Thereby, the physiological implication of Met signalling in immunity 
could be highlighted, when the importance of Met was examined in a disease model 
of  skin inflammation (CHS). The results from in vivo experiments were consistent 
throughout all studies. To address whether Met signalling is also crucial for the 
migration of LC precursors into peripheral tissues for establishing the LC network, 
BM transplantation experiments were carried out. These results showed that Met is 
dispensable for LC precursor immigration into skin. Using in vitro generated DCs, it 
was demonstrated that malfunction of Met signalling affected neither development, 
nor the immune functions of DCs, but Met signalling was shown to be essentially 
involved in regulation of MMP activities, which are required for LC/DC migration 
through ECM. Here, the data demonstrate that Met signalling is not only able to 
induce LC stimulation,,but is essential for the mobilization of LCs and dermal DCs. 
 
Mature DCs express Met, DCs do not express Met ligand  
By transcriptional and flow cytometry analysis of in vitro-generated DCs, Met 
expression turned out to be up-regulated with maturation. Fully differentiated and 
matured in vitro DCs did not produce the Met ligand SF/HGF on mRNA level, 
although their progenitors (Hieronymus et al., 2005) expressed SF/HGF at 
noticeable levels. During DC development, SF/HGF expression was transcriptionally 
down-regulated. DC differentiation or activation with LPS did not recover SF/HGF 
expression in DCs. In contrast, Met expression pattern differed from that of SF/HGF 
expression. In vitro DC progenitors also expressed a considerable level of Met on 
mRNA basis, and Met expression disappeared during GM-CSF-driven DC 
development, but Met expression was elevated again with DC activation (Figure 26).  
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Transferred to in vivo situation, Met expression seems to be suppressed in DC 
precursors during migration to peripheral sites until final differentiation, so that 
differentiating DCs are insensitive to SF/HGF as a mobilization signal. Differentiated 
tolerogenic DCs showed high levels of Met expression comparable to immunogenic 
DCs. In addition, DCs migrated from SF/HGF-treated ear skin biopsy had same 
expression level of Met as DCs from ear skin biopsies treated with pro-inflammatory 
stimuli. From these results, it can be assumed that the up-regulation of Met 
expression in DCs is a consequence of general maturation of peripheral DCs that do 
not depend on DC subtypes or immunomodulatory stimuli.  
 
 
Figure 40. Schematic representation of Met expression throughout the life cycle of 
skin DCs 
 
High levels of Met expression in migratory DCs 
In this study, a detailed analysis on Met expression in different DC subpopulation 
has been performed resulting in the finding that DC subpopulations have different 
levels of Met expression. In vivo, activated migratory DCs entering into LN showed 
the highest levels of Met expression. Interestingly, among migratory DCs, it has been 
observed that LCs migrating with slower kinetics into LN upon activation than dermal 
DCs (Allan et al., 2006; Kissenpfennig et al., 2005) also up-regulated Met expression, 
but at lower levels than dermal DCs. Thus, the migration kinetics of different 
migratory DC subpopulations correlated with Met expression level. CD8+ LN-
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resident DCs displayed also a higher Met expression level that other LN-resident DC 
subpopulations. In vitro generated pDCs showed very high levels of Met expression 
on protein level compared to other DC subpopulations. but high level of Met 
expression in pDCs could not be confirmed in vivo.  In vivo steady-state DCs showed 
comparatively low Met expression on protein level. Probably, stationary DCs express 
only few copies of Met protein. This observation was in line with other studies, which 
reported a relatively low expression level of Met protein in DCs and other Met-
expressing cells such as MDCKs (Bennett et al., 2000; Kurz et al., 2002). Apparently, 
cells expressing Met at low levels are sensitive enough to respond to the stimulus.  
 
Dermal DCs have higher Met expression and faster migration kinetics 
All current assays to assess DC migration have advantages and disadvantages 
(Randolph et al., 2005). The epicutaneous FITC painting assay used here has also 
certain limitations. A known problem of this assay is that low-molecular-weight 
antigens such as FITC can freely flow through interstitium to lymphatics and via 
lymph to the LNs, where they are taken up by lymphoid tissue-resident antigen-
presenting cells (Roozendaal et al., 2009). In the study, it was also noticed that the 
penetrability for FITC is dependent on the concentration and amount of FITC applied 
on the skin (Figure 19). To study DC-mediated FITC transport preventing uptake of 
passively transported FITC by lymphoid tissue-resident, brachial LNs were examined 
as skin-draining LNs instead of inguinal LNs, which are located closer to the site of 
FITC painting (Figure 18). Using FITC painting experiment with C57BL/6 WT, it has 
been found, that dermal DCs have higher Met expression and faster migration 
kinetics towards the draining LN than LCs. Migration kinetics were similar to data 
published by other groups (Allan et al., 2006; Kissenpfennig et al., 2005). But in this 
study, LC arrival in skin-draining lymph nodes was detected earlier than described by 
others. On day 3 after FITC painting, the number of FITC-positive DCs in LNs has 
drastically declined. The explanations can be that (1) inguinal LNs were examined 
for the skin DC kinetics, so that LCs/DCs had a relatively short migratory path. (2) 
Absolute number of LCs and DCs were not shown, and the percentages of these 
cells decreased by the influx of FITC-negative cells into the LNs. It has been 
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described that cell number in LNs steadily increases up to day 3 after FITC painting 
(Fukunaga et al., 2008). 
 
Generation of Met-deficient DCs in vivo           
In vivo migration assays were possible by employing a conditional Met KO mouse 
system based on Mx-Cre system previously established, which has been primarily 
used in conjunction with gastroenterological investigations (Borowiak et al., 2004; 
Giebeler et al., 2009; Marx-Stoelting et al., 2009), as SF/HGF is an important factor 
for liver regeneration. To study the role of Met in the migration of skin DCs in vivo, 
mice bearing Met KO DCs in skin were required. To generate conditional Met KOs, 
Mx-Cre x Metflox/- transgenic mice were subjected to various treatments. The positive 
control group with WT phenotype consisting of Mx-Cre x Metflox/+ transgenic mice 
were treated in the same way as conditional KOs. The control group also expressed 
Cre recombinase upon treatment with pI:pC. In doing so, it was intended to avoid 
misinterpretation of the pI:pC treatment effects and the prospective interference of 
Cre recombinase with DC functions in the results. Concerning pI:pC injections, it was 
taken into consideration that peripheral DCs were supposed to be activated and 
removed after a systemic administration of pro-inflammatory agents such as pI:pC, 
LPS and CpG motifs (Ban et al., 2000; Mattei et al., 2009; Roake et al., 1995). Also 
without such stimuli all DC are subjected to turnover with different rates. For our in 
vivo migration assays, LC/DC reconstitution following pI:pC treatments and naturally 
occurring homeostatic turnover was preconditioned. Homeostatic DC turnover time 
was described to vary for different DC subpopulations from 24 hours to 4 weeks and 
even to more than 18 months for LCs (Merad and Manz, 2009).  
To estimate the efficiency of Cre recombinase-mediated gene excision, different 
organs and in vitro cultured cells from conditional Met KOs were regenotyped after 
pI:pC injections Regenotyping of the tail cuts and ear sheets revealed that the 
efficiency of gene recombination was low in these tissues and that the recombination 
efficiency was in general not the same in every tissue. Genotyping is a qualitative 
method, which does not give any information about the degree of excision and where 
one can distinguish only between two situations, namely almost complete to 
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complete and incomplete excision. Estimating the efficiency of gene excision in skin 
LCs/DCs was difficult. On the one hand, it was difficult to figure out, how efficient the 
Cre-mediated recombination was in the skin, because some non-haematopoietic 
cells, such as fibroblasts or epidermal keratinocytes, seemed to be just resistant to 
the systemic pI:pC treatment resulting in incomplete gene deletion. On the other 
hand, it was also difficult to monitor the gene deletion in skin-residing LCs and DCs, 
because their purification to sufficient number and purity e. g. by MACS or FACS 
sorting was not possible. For some in vivo migration assay experiments, Mx-Cre x 
Metflox/- mice were additionally injected with LPS intraveniously prior to intraperitoneal 
pI:pC injections to ensure fast turnover of Met WT LCs and replacement by BM-
derived Met KO cells in the peripheral skin tissue. Cre-mediated deletion of floxed 
gene sequences is known to never reach 100% in whole organism, but it has been 
reported to be particularly efficient for the BM (Kuhn et al., 1995; Schneider et al., 
2003). Here, it was also observed by regenotyping of BM that the gene excision was 
almost complete (Figure 11). 
In the Mx-Cre-based inducible conditional knockout model all cell types can be 
potentially converted into Met deficient cells. Thus, it can be speculated whether 
Met-expressing cell types other than LCs and DCs contribute LC/DC migration. 
Other cells are also known to up-regulate MMP-9 in response to SF/HGF, which in 
secreted form can theoretically support LC/DC migration (Bennett et al., 2000). In 
2007, Caton et al. generated a mouse strain expressing Cre recombinase under the 
control of the DC-specific CD11c promoter (Caton et al., 2007). Using this mouse 
model in combination with the floxed Met gene, Met would be knocked out only in 
DCs. In order to focus on the Met function exceptionally in DCs or LCs, a CD11c-
Cre-based conditional knockout model can be more advantageous than the Mx-Cre 
system. To further narrow down the study of Met function to LCs, the use of 
Langerin-Cre can be taken into consideration (Kaplan et al., 2007). 
It was important to examine whether, in the ear skin of conditional Met KO, Met KO 
progenitors are able to repopulate skin or LCs and DCs are derived only from 
progenitors harbouring unexcised Met gene resulting from incomplete gene excision. 
With LC/DC reconstitution experiment with CD45.2 KO BM-> CD45.1 mice, it was 
proven that LCs and skin DCs stay Met deficient still several weeks after pI:pC 
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injections. Met has been revealed to be not essential for LC/DC development and 
reconstitution, because DC repopulation in Met deficient mice worked normally. The 
result showed in addition that LCs and DCs could be reconstituted from Met KO BM.  
 
Signalling incompetence in Met-deficient DCs 
To study the effect of Met deficiency, Met signalling was further studied in in vitro 
generated DCs using Western blot analysis. Gene deletion in the BM was sufficient 
to inactivate SF/HGF-triggered MAPK signalling in BM-derived cells (Figure 28). 
Recently, Klemke et al. identified the Ras-MAPK-cofilin pathway as a signalling 
module that dissects features of the migratory plasticity of T lymphocytes in a 3D 
interstitial environment (Klemke et al., 2010). Some studies have also shown that the 
MAPK/ERK pathway is involved in Met-triggered migration in various cell types 
(Ishibe et al., 2003; Karihaloo et al., 2001; Segarra et al., 2006). Detection of Met 
excision on the protein level is not possible. Thus, Met function had to be shown in 
an indirect way, e. g. by Western blot analysis of Erk1/2 phosphorylation.  
 
SF/HGF production in non-DCs upon inflammation 
Until now, many studies on Met function in DCs have mainly focussed on identifying 
Met as immunoregulatory factor (Benkhoucha et al., 2010; Kuroiwa et al., 2006; 
Okunishi et al., 2005; Rutella et al., 2006a; Rutella et al., 2006b). In this study, 
SF/HGF could not be verified as an immunoregulatory factor, since SF/HGF did not 
inhibit immunogenic function of activated DCs, such as T-cell activation and cytokine 
production. In vitro generated DCs did not re-arrange their repertoire of surface 
markers including co-stimulatory markers and chemokine receptors to acquire 
migration aptitudes after SF/HGF stimulation. In some reports, SF/HGF was 
described as a DC poietin (Ovali et al., 2000; Rutella et al., 2006a; Sonmez et al., 
2007; Zou and Tam, 2002). Here, SF/HGF was also not identified as a DC poietin at 
least in the mouse system because (1) murine DC progenitors (Hieronymus et al., 
2005) and BM cells could not survive in vitro with SF/HGF only, (2), when WT DCs 
were generated in vitro with GM-CSF and SF/HGF together, DCs did not differ from 
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DCs generated with GM-CSF only (Figure 29), and (3) DC generation from Met KO 
cultured with GM-CSF or Flt3-ligand also showed normal DC development (Figure 
29). Taken together, it could be concluded that SF/HGF is neither an 
immunoregulatory factor nor a DC poietin in mouse system.  
SF/HGF is known to be produced by various mesenchymal cell types and acts as a 
paracrine factor on Met-expressing cells located in close proximity. Stromal 
fibroblasts, vascular endothelial and smooth muscle cells, neutrophils and mast cells 
are major sources of SF/HGF (Jiang et al., 2005). Production of SF/HGF is known to 
be positively regulated with pro-inflammatory stimuli and negatively regulated with 
anti-inflammatory stimuli (Gohda et al., 1992a; Gohda et al., 1994; Gohda et al., 
1992b; Inaba et al., 1993; Liu et al., 1994; Tamura et al., 1993), which supports the 
importance of SF/HGF/Met signalling in infection and inflammation.  
 
 
Figure 41. Schematic representation of SF/HGF production during infection/skin injury  
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Crosstalk of Met signalling with pro-inflammatory stimuli 
Both inflammatory intercellular messengers, IL-1β and TNF-α, have been regarded 
as main stimuli, which are both required and sufficient for DC migration (Alvarez et 
al., 2008; Cumberbatch et al., 1997a; Cumberbatch et al., 1997b). In ex vivo 
migration experiments, it has been shown that Met ligand SF/HGF could mobilize 
LCs without any involvement of pro-inflammatory stimuli, such as LPS and TNF-α 
(Kurz et al., 2002). Ex vivo migration experiments with Met KO mice revealed that 
Met kinase activity is essential for LC/DC mobilization from skin independent from 
any additional stimuli. According to published data, there are diverse means to 
activate Met tyrosine kinase in absence of its ligand SF/HGF. However, from the 
experiments performed in this study it can be concluded that Met kinase is 
irreplaceable in the process of LC emigration.  
LCs are well charged with PRRs for various PAMPs, but are supposed to lack TLR-4, 
the PRR for LPS. Here, in line with previously published data it has been observed 
that the treatment of ear skin biopsies with LPS induces LC migration from the 
epidermal tissue. Several investigators verified that following LPS treatments of 
purified human and mouse LCs both did not get activated at all or only poorly 
(Flacher et al., 2006; Mitsui et al., 2004; Roake et al., 1995). These observations 
suggest the contribution of other cell types to the emigration process of LCs and 
indicate the complexity of the interaction among the participants. This suggestion 
supports a lively ongoing discussion, which cells control skin immunity under 
physiological conditions, where T cells, DCs or keratinocytes have all the potential to 
be called protagonist (Nestle et al., 2009; Reich, 2006). Based on these observations, 
the skin immunity is not maintained by the solo attempt of one specific cell type, but 
rather by a team play of various skin-resident cell types, in which intercellular 
interactions and communications via cytokines and growth factors between these 
different cell types are requisite. This study provides strong evidence that SF/HGF 
plays a role as one of the intermediate messengers between different cell types. 
Among skin-resident cells, fibroblasts that populate dermal compartment of the skin 
promote dermal-epidermal interactions providing mesenchyme-derived messenger 
substances (Saalbach et al., 2010; Sorrell and Caplan, 2004). Under steady-state 
conditions, DCs are stationary embedded in extracellular matrices or cell-cell 
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networks. SF/HGF itself is not a pro-inflammatory factor, but it is supposed to come 
along with inflammation (Liu et al., 1994; Matsunaga et al., 1994; Mildner et al., 2007; 
Nayeri et al., 2006; Tamura et al., 1993). Recently, Saalbach et al. reported that 
interaction of DCs with TNF-α/IL-1β-stimulated fibroblasts increased the secretion of 
matrix metalloprotease-9 from DCs in an IL-6 dependent manner. This model is in 
line with our concept, and it would be interesting to examine whether and how far 
SF/HGF is involved in this migration process. Together with the observations in 
functional assays with in vitro-generated DCs, the regulation of SF/HGF production 
supports the importance of SF/HGF in activation of the immune system. 
 
Impact of TGF- β signalling on Met expression in LC  
In in vitro cultures, the presence of TGF-β during differentiation promoted elevated 
Met expression in differentiated GMDCs on both mRNA and protein levels. As  the 
epidermal microenvironment is described to be TGF-β rich by the expression in 
keratinocytes and LCs (Borkowski et al., 1996) and TGF-β expression is additively 
induced during inflammation (Schmid et al., 1993), Met expression is potentially 
maintained by TGF-β in steady-state and inflammatory interstitial DCs in vivo. TGF-β 
signalling turned out to be indispensable for LC development, confirmed by KO 
mouse models, such as TGF-β KOs and knockouts of its downstream transcription 
factor Id2, which both lack LCs (Borkowski et al., 1996; Fainaru et al., 2004; Hacker 
et al., 2003). TGF-β is known as a mobilizing factor for cancer cells (Christofori, 
2006), but it exerts the opposite function on LCs. During LC development, TGF-β 
even increases E-cadherin expression, which is important for anchoring to 
keratinocytes, the main constituent in the epidermis (Riedl et al., 2000). 
 
Met signalling regulates MMP activity on surface of DCs 
Met-initiated migratory activity in various cell types is usually accompanied by distinct 
phenotypical changes including disruption of intercellular junctions, retraction and 
exfoliation, and exposure to underlying extracellular matrix, which are referred to as 
epithelial-mesenchymal transition (EMT) (Demir Weusten et al., 2000). The EMT is 
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known as a consequence of the activation of signalling cascades through 
membrane-associated proteins including extracellular matrix components such as 
collagen and other soluble factors such as EGF, IGF, FGF and TGF-β etc (Boyer et 
al., 2000). SF/HGF is also highly potent inducer of EMT (Gavrilovic et al., 1990; 
Morali et al., 2001; Piek et al., 1999; Savagner, 2001; Strutz et al., 2002; Valles et al., 
1990).  In this study, LCs and dermal DCs are supposed to undergo an EMT-like 
transformation by Met signalling. One indication of such a transformation of DCs was 
provided by showing regulation of MMP activity in response to Met signalling. MMP 
activity is a distinct part of the EMT mechanism, and some MMPs have even been 
shown to initiate the EMT process (Orlichenko and Radisky, 2008; Przybylo and 
Radisky, 2007). Type IV collagenases, especially MMP-9, have been already 
elaborately described by different groups to be necessary for the migration of LCs 
and dermal DCs from human and murine skin (Kobayashi et al., 1999; Ratzinger et 
al., 2002; Yen et al., 2008). In this study, Met function on the cellular level has been 
investigated with in vitro generated DCs. Generating DCs in vitro DCs with GM-CSF 
was preferred, because they showed features comparable to LCs/dermal DCs from 
ex vivo migration assay (Figures 17 and 27). In addition, GM-CSF-derived DCs had 
the advantage of being more homogenous than Flt3-ligand-derived DCs comprising 
pDCs, CD8α- and CD8α+ DC subpopulations. GM-CSF-derived DCs in vitro 
resemble inflammatory DCs found in vivo (Xu et al., 2007). The progenitors of GM-
CSF-derived DCs were Flt3+CD11b+ cells described by Hieronymus et al. 
(Hieronymus et al., 2005). To test their physiological relevance, in vitro amplified 
Flt3+CD11b+ DC progenitor cells were adoptively injected into mice, and foundto 
give rise to functional DCs in vivo, including steady-state DCs among others 
(Hieronymus et al., 2005). Additionally, Ober-Blöbaum et al. could show by adoptive 
transfer assays that in vitro amplified Flt3+CD11b+ DC progenitors reconstitute skin 
DCs (Ober-Blöbaum 2009). When LPS-activated GMDCs were treated with SF/HGF, 
an up-regulation of membrane-bound MMP-9 activity in DCs has been observed, 
which seem not to be transcriptionally regulated, but in a rather post-translational 
fashion. In contrast, a down-regulation of membrane-bound MMP-2 activity in 
activated DCs upon SF/HGF stimulation was observed. Interestingly, MMP-2 and 
MMP-9 regulation in GMDCs was in line with data from a study of PGE2-induced 
MMP regulation in monocytes from the literature (Yen et al., 2008). Several authors 
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have also shown that keratinocytes are able to secrete MMP-9 upon inflammation 
(Bahar-Shany et al., 2010; Purwar et al., 2008) or upon SF/HGF stimulation (Bennett 
et al., 2000). Thus, based on these observations, the membrane-bound form of 
MMP-9 on migratory DCs is supposed to be more crucial for transmigration through 
extracellular matrix barriers (Alvarez et al., 2008). 
 
Concluding remarks 
Taken together, our data demonstrate that Met signalling is critically involved in the 
emigration of LCs and dermal DCs from peripheral skin tissue and thus play an 
important role in skin immunity. These findings further suggest a more fundamental 
regulatory function of Met signalling for DC migration particularly for trafficking of 
other interstitial DC subpopulations from peripheral tissues towards secondary 
lymphoid organs.  
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FUTURE PERSPECTIVES 
The data provided no evidence for an impact of Met signalling on DC development 
and immunological functions of differentiated DCs such as antigen uptake, 
processing, and presentation to T cell, cytokine production and surface marker 
expression. However, SF/HGF was found to be constitutively produced by fibroblast-
like stromal cells from human lymphoid tissue and modulated by activated T cells 
(Gordin et al., 2010). Thus, it may be interesting to address, whether SF/HGF plays 
additional roles on DCs within lymphoid organs such as regulation of cell survival.  
Met signalling has been shown to be vital in embryogenesis by regulating a 
motogenic, morphogenic, and mitogenic program (also termed as invasive growth) in 
cells leading to the transient conversion from an epithelial to a mesenchymal 
phenotype followed by well-controlled cell migration (Birchmeier et al., 2003; 
Boccaccio and Comoglio, 2006). This program can be reactivated in adult life during 
tissue repair and organ regeneration.  Thus, Met signalling in DCs appears to 
recapitulate this embryogenic developmental programme including detachment form 
primary tissue, adherence to and migration through ECM, and crossing tissue 
boundaries. Regulation of MMP activities by Met, as shown here, is essentially 
involved in this programme in DCs but most likely not sufficient to control all 
sequential steps. Thus, further Met-dependent mechanisms that control this 
programme remain to be identified. Especially in the epithelium, where LCs reside, 
intercellular adhesion is primarily mediated by adherens junctions. Physical 
association between neighbouring cells is maintained by cadherins, which are 
connected to catenins that form a submembraneous scaffold to structurally and 
functionally link cadherins to the actin microfilaments. From investigations in tumour 
cell biology, it is known that SF/HGF and Met signalling actively contribute to 
destabilization of adhesion by redistribution of the cadherin-catenin complexes form 
the actin cytoskeleton to the soluble membrane fraction, and by disruption of the 
structural integrity of adherens junctions by tyrosine phosphorylation of catenin 
(Trusolino and Comoglio, 2002). All of these regulatory mechanisms have not been 
investigated in DCs yet.  
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Analysis of Met signalling-mediated adherens junction pathways in DCs and 
investigation of post-transcriptional and -translational regulation of actin remodelling 
proteins like cofilin by Met signalling (Klemke et al., 2010) would be interesting topics 
for further research.  
Met is predominantly expressed on epithelial cells, but has also been implicated in 
haematopoiesis (Kmiecik et al., 1992). So far, only a limited number of studies have 
evaluated the role of Met in the immune system. Met is known to be expressed in 
haematopoietic stem cells and in their antigen-presenting progeny including 
activated B cells, monocytes, macrophages, and DCs. However, not all 
haematopoietic stem cells express Met, including e.g. T cells (Beilmann et al., 2000; 
Benkhoucha et al., 2010; Okunishi et al., 2005; Rutella et al., 2006a; Rutella et al., 
2006b; Skibinski et al., 2001). Interestingly, Met-expressing cells also express the 
MHC class II molecule and often up-regulate Met and MHC class II upon activation, 
as demonstrated in DCs and B cells (Skibinski et al., 2001). Reports showed that a 
splice variant of CD44 is a co-receptor and regulator of Met function (Christofori, 
2006; Matzke et al., 2007). CD44 and MHC class II-associated protein invariant 
chain Ii/CD74 interact with each other and both are found to be important for immune 
cell migration by actin cytoskeleton regulation (Naujokas et al., 1993; Shi et al., 2006; 
Vascotto et al., 2007). This suggests an interaction between Met and CD74 and 
even a contribution of Met in actin cytoskeleton regulation via CD74. 
Since Met is an initiating and necessary component for the invasive growth and 
metastasis of tumours, Met has been considered as one of the versatile candidates 
for targeted therapeutic intervention. Different approaches, such as biological 
antagonists, including antibodies against SF/HGF and Met, and small-molecule Met 
inhibitors, are attempted for inhibition of Met function (Comoglio et al., 2008). By now, 
the effect of Met inhibition on immune function has not been taken into consideration. 
During Met inhibitor-based tumour therapy, not only tumour cells are restrained from 
executing migratory activities, but also antigen-presenting DCs might be immobilized 
by Met inhibitors. Thus, in Met inhibitor-based tumour therapy, it seems to be 
important to consider possible immunological consequences of Met inhibition. 
However, positioning Met signalling ahead in controlling DC emigration from 
peripheral tissues, such as skin, makes it a potentially attractive target for the 
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treatment of auto-immune skin diseases or other auto-immune disorders and in 
transplantation. Therefore, future investigations should address, immunological 
consequences and side effects that can occur during treatment of cancer with Met 
inhibitors and whether Met inhibitors can be employed for the treatment of auto-
immune disorders, such as psorias.  
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APPENDIX 
Rapid method for preparation of genomic DNA 
Mouse tails were lysed in 500 µl of 50 mM NaOH for 3 h at 95°C and then buffered 
with 50 µl of 1 M Tris/HCl + 10 mM EDTA. The lysates were centrifuged down for 1 
min at maximum speed in the table centrifuge. 
 
Conditions for genotyping of Mx-Cre x Met+/- mice 
Mx-Cre FW: 5’-TTCACggTTTCAATTCTCCTCTgg-3’ 
Mx-Cre RV: 5’-CACCggCATCAACgTTTTCTTTC-3’ 
 
PCR reaction mix 
2 µl DNA isolated by “quick and dirty” method 
5 µl 10x taq Pol buffer (NH4)2SO4 
3 µl MgCl2 
2 µl FW primer, 10 mM 
2 µl RV primer, 10 mM 
2 µl dNTP (10 mM each) 
1 µl Recombinant Taq DNA Polymerase (Fermentas) 
+ 33 µl H2O, total volume: 50 µl 
 
Reaction scheme 
   
 
 
Initiation 94°C 2 min 
Denaturation 92°C 60 sec 
Annealing 61°C 90 sec 
Extension 72°C 2 min 
Final extension 72°C 7 min 
Termination 4°C ∞ 
40x 
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KO-Met FW:  5’-CTTgCgTgCAATCCATCTTgTTCAATg -3’ 
KO-Met RV:  5’-CACTgAgCCCAgAAgAgCTAgTgg-3’ 
 
PCR reaction mix 
2 µl DNA isolated by “quick and dirty” method 
5 µl 10x taq Pol buffer (NH4)2SO4 
6 µl MgCl2 
2 µl FW primer, 10 mM 
2 µl RV primer, 10 mM 
2 µl dNTP (10 mM each) 
1 µl Recombinant Taq DNA Polymerase (Fermentas) 
+ 30 µl H2O, total volume: 50 µl 
 
 
 
WT-Met FW: 5’-CTTTTTCAATAgggCATTTTggCTgTg-3’ 
WT-Met RV:  5’-gTACACTggCTTgTACAATgTACAgTTg-3’ 
 
PCR reaction mix 
2 µl DNA isolated by “quick and dirty” method 
5 µl 10x taq Pol buffer (NH4)2SO4 
3 µl MgCl2 
2 µl FW primer, 10 mM 
2 µl RV primer, 10 mM 
2 µl dNTP (10 mM each) 
1 µl Recombinant Taq DNA Polymerase (Fermentas) 
+ 33 µl H2O, total volume: 50 µl 
 
 
Reaction scheme for both Met WT and KO genotyping 
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Conditions for genotyping of Mx-Cre x Metflox/? mice 
fl-Met WT: 5’-AgCCTAgTggAAATCTCTgTAAg-3’ 
fl-Met KO: 5’-CCAAgTgTCTgACggCTgTg-3’ 
 
PCR reaction mix 
2 µl DNA isolated by “quick and dirty” method 
5 µl 10x taq Pol buffer (NH4)2SO4 
3 µl MgCl2 
2 µl FW primer, 10 mM 
2 µl RV primer, 10 mM 
2 µl dNTP (10 mM each) 
1 µl Recombinant Taq DNA Polymerase (Fermentas) 
+ 33 µl H2O, total volume: 50 µl 
 
Reaction scheme 
   
 
  
Initiation 94°C 2 min 
Denaturation 94°C 45 sec 
Annealing 66°C 30 sec 
Extension 72°C 65 sec 
Final extension 72°C 1 min 
Termination 4°C ∞ 
Initiation 94°C 2 min 
Denaturation 96°C 60 sec 
Annealing 60°C 90 sec 
Extension 72°C 2 min 
Final extension 72°C 7 min 
Termination 4°C ∞ 
35x 
35x 
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